<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:voc="urn:hl7-org:v3/voc" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="89cf3273-b943-2e6b-1137-5c0b76784a88"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use LISDEXAMFETAMINE DIMESYLATE CAPSULES safely and effectively. See full prescribing information for <content styleCode="bold">LISDEXAMFETAMINE DIMESYLATE CAPSULES</content>.<content styleCode="bold">
            <br/>
            <content styleCode="bold">LISDEXAMFETAMINE DIMESYLATE </content>
         </content>
         <content styleCode="bold">capsules, for oral use, CII<content styleCode="bold">
               <br/>Initial U.S. Approval: 2007</content>
         </content>
      </content>
   </title>
   <effectiveTime value="20241204"/>
   <setId root="ecad4442-a644-18e3-6ff2-fdbac45eec47"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="845263701" root="1.3.6.1.4.1.519.1"/>
            <name>Apotex Corp.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="209429182" root="1.3.6.1.4.1.519.1"/>
                  <name>Apotex Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="080243260" root="1.3.6.1.4.1.519.1"/>
                        <name>Frontida BioPharm, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4739" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4740" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4741" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4742" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4743" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4744" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4745" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4739" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4740" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4741" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4742" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4743" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4744" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-4745" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="97a98e82-8c29-5242-cbb6-a0da6db78317"/>
               <code code="48780-1" displayName="SPL PRODUCT DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20241204"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-4739" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Lisdexamfetamine Dimesylate</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Lisdexamfetamine Dimesylate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="SJT761GEGS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Lisdexamfetamine Dimesylate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="H645GUL8KJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Lisdexamfetamine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Croscarmellose Sodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Magnesium Stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Titanium Dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PN2ZH5LOQY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Fd&amp;C Red No. 3</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZH3C48M4T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Potassium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Shellac</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ammonia</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T65PN3O37H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Propylene Glycol 1,2-Distearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferrosoferric Oxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4739-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20231109"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231109"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216944" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" displayName="PINK" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText>pink</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;L10</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="14" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-4740" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Lisdexamfetamine Dimesylate</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Lisdexamfetamine Dimesylate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="SJT761GEGS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Lisdexamfetamine Dimesylate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="H645GUL8KJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Lisdexamfetamine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Croscarmellose Sodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Magnesium Stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Titanium Dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferric Oxide Yellow</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Shellac</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T65PN3O37H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Propylene Glycol 1,2-Distearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ammonia</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferrosoferric Oxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4740-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20231109"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231109"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216944" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText>white Ivory</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;L20</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="14" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-4741" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Lisdexamfetamine Dimesylate</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Lisdexamfetamine Dimesylate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="30"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="SJT761GEGS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Lisdexamfetamine Dimesylate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="H645GUL8KJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Lisdexamfetamine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Croscarmellose Sodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Magnesium Stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Titanium Dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Fd&amp;C Yellow No. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PN2ZH5LOQY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Fd&amp;C Red No. 3</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Shellac</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T65PN3O37H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Propylene Glycol 1,2-Distearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ammonia</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferrosoferric Oxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4741-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20231109"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231109"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216944" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" displayName="ORANGE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="14" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;L30</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-4742" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Lisdexamfetamine Dimesylate</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Lisdexamfetamine Dimesylate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="40"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="SJT761GEGS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Lisdexamfetamine Dimesylate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="H645GUL8KJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Lisdexamfetamine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Croscarmellose Sodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Magnesium Stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Titanium Dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Fd&amp;C Blue No. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferric Oxide Yellow</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Shellac</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ammonia</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T65PN3O37H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Propylene Glycol 1,2-Distearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferrosoferric Oxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4742-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20231109"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231109"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216944" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" displayName="GREEN" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;L40</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="14" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-4743" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Lisdexamfetamine Dimesylate</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Lisdexamfetamine Dimesylate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="50"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="SJT761GEGS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Lisdexamfetamine Dimesylate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="H645GUL8KJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Lisdexamfetamine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Croscarmellose Sodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Magnesium Stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Titanium Dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Fd&amp;C Blue No. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Shellac</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ammonia</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T65PN3O37H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Propylene Glycol 1,2-Distearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferrosoferric Oxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4743-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20231109"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231109"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216944" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" displayName="BLUE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;L50</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-4744" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Lisdexamfetamine Dimesylate</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Lisdexamfetamine Dimesylate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="60"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="SJT761GEGS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Lisdexamfetamine Dimesylate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="H645GUL8KJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Lisdexamfetamine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Croscarmellose Sodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Magnesium Stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Titanium Dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Fd&amp;C Blue No. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Shellac</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ammonia</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T65PN3O37H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Propylene Glycol 1,2-Distearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferrosoferric Oxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4744-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20231109"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231109"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216944" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" displayName="BLUE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;L60</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-4745" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Lisdexamfetamine Dimesylate</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Lisdexamfetamine Dimesylate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="70"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="SJT761GEGS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Lisdexamfetamine Dimesylate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="H645GUL8KJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Lisdexamfetamine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Croscarmellose Sodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Magnesium Stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Titanium Dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Fd&amp;C Yellow No. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PN2ZH5LOQY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Fd&amp;C Red No. 3</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Fd&amp;C Blue No. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Shellac</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ammonia</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T65PN3O37H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Propylene Glycol 1,2-Distearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferrosoferric Oxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="60505-4745-1"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20231109"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231109"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216944" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" displayName="BLUE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" displayName="ORANGE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;L70</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <section>
                     <id root="7754ed3a-3a35-037e-d625-4615439e7051"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <effectiveTime value="20220125"/>
                     <component>
                        <observationMedia ID="MM188718933344">
                           <text>structure.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="structure.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM891508802937">
                           <text>figure-1.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure-1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM828767931450">
                           <text>figure-2.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure-2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM548774666486">
                           <text>figure-3.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure-3.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM862504623320">
                           <text>figure-4.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure-4.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM669656274193">
                           <text>figure-5.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure-5.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM598493153659">
                           <text>figure-6.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure-6.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM598341453060">
                           <text>figure-7.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure-7.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM697031100865">
                           <text>figure-8.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure-8.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM102103952158">
                           <text>bottle-label-10mg-100s.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="bottle-label-10mg-100s.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM544434860732">
                           <text>bottle-label-20mg-100s.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="bottle-label-20mg-100s.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM635294604935">
                           <text>bottle-label-30mg-100s.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="bottle-label-30mg-100s.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM335033868044">
                           <text>bottle-label-40mg-100s.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="bottle-label-40mg-100s.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM301125462943">
                           <text>bottle-label-50mg-100s.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="bottle-label-50mg-100s.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM388766615699">
                           <text>bottle-label-60mg-100s.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="bottle-label-60mg-100s.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM73930055298">
                           <text>bottle-label-70mg-100s.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="bottle-label-70mg-100s.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="BOXED_WARNING">
               <id root="a3d04f20-9572-4870-cfca-18fe457e608f"/>
               <code code="34066-1" displayName="BOXED WARNING SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">WARNING: ABUSE, </content>
                  <content styleCode="bold">MISUSE, AND ADDICTION</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange"/>
                     <content styleCode="xmChange"/>
                     <content styleCode="bold">Lisdexamfetamine dimesylate capsules</content>
                     <content styleCode="bold"> has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including lisdexamfetamine dimesylate capsules, can result in overdose and death </content>
                     <content styleCode="bold italics">[see Overdosage (<linkHtml href="#OVERDOSAGE">10</linkHtml>)]</content>
                     <content styleCode="bold italics">,</content>
                     <content styleCode="bold"> and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="xmChange"/>
                     <content styleCode="xmChange"/>
                     <content styleCode="bold">Before prescribing lisdexamfetamine dimesylate capsules, assess each patients risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout lisdexamfetamine dimesylate capsules treatment, reassess each patients risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction </content>
                     <content styleCode="bold italics">[see Warnings and Precautions (<linkHtml href="#_1c87c681-652b-26d1-f5e9-c4bcf6a09df7">5.1</linkHtml>), </content>
                     <content styleCode="bold italics">Drug Abuse and Dependence (<linkHtml href="#ABUSE">9.2</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20231220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING:ABUSE<content styleCode="bold">, MISUSE, AND ADDICTION</content>
                           </content>
                           <content styleCode="bold">
                              <br/>
                           </content>
                           <content styleCode="bold italics">Seefullprescribinginformationfor completeboxedwarning.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Lisdexamfetamine Dimesylate capsules</content>
                           <content styleCode="bold"> has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction.</content>
                           <content styleCode="bold"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Misuse and abuse of CNS stimulants, including </content>
                           <content styleCode="bold">lisdexamfetamine dimesylate capsules</content>
                           <content styleCode="bold">, can result in overdose and death (5.1, <linkHtml href="#ABUSE"> 9.2</linkHtml>, </content>
                           <content styleCode="bold"> 10</content>
                           <content styleCode="bold">):</content>
                        </paragraph>
                        <list>
                           <item>
                              <content styleCode="bold">Before prescribing </content>
                              <content styleCode="bold">lisdexamfetamine dimesylate capsules</content>
                              <content styleCode="bold">, assess each patients risk for abuse, misuse, and addiction.</content>
                              <content styleCode="bold"/>
                           </item>
                           <item>
                              <content styleCode="bold">Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug.</content>
                              <content styleCode="bold"/>
                           </item>
                           <item>
                              <content styleCode="bold">Throughout treatment, reassess each patients risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_57de682b-de66-e8ac-1761-5e14e4d71d80">
               <id root="aa1b0337-2d39-7ebc-251a-e27aeaf9fa92"/>
               <code code="43683-2" displayName="RECENT MAJOR CHANGES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>RECENT MAJOR CHANGES SECTION</title>
               <effectiveTime value="20231102"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Boxed Warning 10/2023</paragraph>
                        <paragraph>Dosage and Administration (<linkHtml href="#_b4410b38-5581-fcb5-39b3-9c4b0f013528">2.1</linkHtml>) 10/2023 </paragraph>
                        <paragraph>Warnings and Precautions (<linkHtml href="#_55b8f6eb-b923-8986-ec3f-cf5561192d43">5.1</linkHtml>, <linkHtml href="#_d2108e06-f1e5-9e1a-86a2-59273bf634b1">5.2</linkHtml>, <linkHtml href="#_05b1693a-479c-425e-2e57-26a72f39fe27">5.3</linkHtml>, <linkHtml href="#_889fcaf4-adff-dea8-4a22-0b65ea3c99f9">5.4</linkHtml>, <linkHtml href="#_6dc62472-9038-1776-e43e-30fa4c123dd3">5.5</linkHtml>, <linkHtml href="#_1c87c681-652b-26d1-f5e9-c4bcf6a09df7">5.6</linkHtml>, <linkHtml href="#_2b5540af-9f6a-b20a-b6fb-2cd3c1bbf342">5.8</linkHtml>) 10/2023</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="INDICATIONS_AND_USAGE">
               <id root="9da1e042-4ef0-f09e-717e-4186ce479f42"/>
               <code code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Lisdexamfetamine dimesylate capsulesareindicatedforthetreatmentof:</paragraph>
                  <list>
                     <item>
                        <content styleCode="none"/>Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 yearsandolder <content styleCode="italics">[see Clinical Studies(<linkHtml href="#_bab39eaf-3540-8541-210f-5c88ca1ef1bb">14.1</linkHtml>)]</content>
                     </item>
                     <item>Moderatetoseverebingeeatingdisorder (BED)inadults <content styleCode="italics">[seeClinicalStudies(<linkHtml href="#_ce13a1ec-8b23-c88d-70c0-b8a8197151dd">14.2</linkHtml>)]</content>.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Limitations ofUse:</content>
                  </paragraph>
                  <list>
                     <item>
                        <content styleCode="none"/>
                        <content styleCode="none"/>Pediatricpatients withADHDyounger than6yearsofageexperiencedmorelong-termweight lossthan patients6 years andolder<content styleCode="italics">[see Usein SpecificPopulations(<linkHtml href="#PEDIATRIC_USE">8.4</linkHtml>)]</content>.</item>
                     <item>
                        <content styleCode="none"/>Lisdexamfetamine dimesylate capsules are not indicated or recommended for weight loss. Use of othersympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of lisdexamfetamine dimesylate capsules for the treatment of obesityhavenot been established <content styleCode="italics">[seeWarnings and Precautions(<linkHtml href="#_6dc62472-9038-1776-e43e-30fa4c123dd3">5.2</linkHtml>)]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20220125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Lisdexamfetamine dimesylate capsulesareacentralnervous system(CNS)stimulantindicatedforthetreatmentof (<linkHtml href="#INDICATIONS_AND_USAGE">1</linkHtml>):</paragraph>
                        <list>
                           <item>Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatricpatients6 years and older</item>
                           <item>Moderatetosevere bingeeatingdisorder (BED)inadults</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">LimitationsofUse:</content>
                        </paragraph>
                        <list>
                           <item>PediatricpatientswithADHDyounger than6yearsofageexperiencedmorelong-termweight lossthanpatients 6 yearsand older(<linkHtml href="#PEDIATRIC_USE">8.4</linkHtml>)</item>
                           <item>Lisdexamfetamine dimesylate capsules are not indicated for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascularadverse events.The safety and effectiveness of lisdexamfetamine dimesylate capsules for thetreatment ofobesity havenotbeen established(<linkHtml href="#_6dc62472-9038-1776-e43e-30fa4c123dd3">5.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="DOSAGE_AND_ADMINISTRATION">
               <id root="31a6c956-cbc5-5c3a-f67e-d0c9f2aaa3ea"/>
               <code code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20220125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table frame="border" rules="all">
                           <tbody>
                              <tr>
                                 <td> IndicatedPopulation </td>
                                 <td> InitialDose </td>
                                 <td> TitrationSchedule </td>
                                 <td> RecommendedDose </td>
                                 <td> MaximumDose </td>
                              </tr>
                              <tr>
                                 <td> ADHD (Adults andpediatricpatients6years andolder) (<linkHtml href="#_84b0066f-fad5-120f-e954-9929b2b53b22">2.2</linkHtml>) </td>
                                 <td> 30 mgeverymorning </td>
                                 <td> 10mgor 20 mgweekly </td>
                                 <td> 30 mg to 70mgperday </td>
                                 <td> 70 mgperday </td>
                              </tr>
                              <tr>
                                 <td> BED (Adults)(<linkHtml href="#_4f777e54-bf46-3e4b-45cc-e898bda0c446">2.3</linkHtml>) </td>
                                 <td> 30 mgevery morning </td>
                                 <td> 20 mgweekly </td>
                                 <td> 50 mg to 70mgperday </td>
                                 <td> 70 mgperday </td>
                              </tr>
                           </tbody>
                        </table>
                        <list>
                           <item>Priortotreatment,assessforpresence ofcardiacdisease (<linkHtml href="#_565b71d1-35fb-4d11-bbe3-3da0074577af">2.4</linkHtml>)</item>
                           <item>Severerenalimpairment:Maximumdoseis50mg/day (<linkHtml href="#_fd14dd65-3a19-d2b1-98e7-4073315ba37d">2.5</linkHtml>)</item>
                           <item>Endstagerenaldisease(ESRD): Maximumdoseis30 mg/day(<linkHtml href="#_fd14dd65-3a19-d2b1-98e7-4073315ba37d">2.5</linkHtml>)</item>
                        </list>
                        <paragraph/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_2b5540af-9f6a-b20a-b6fb-2cd3c1bbf342">
                     <id root="888b1bfd-e244-6705-f0af-a2e8ed1f7aaa"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.1 Pretreatment Screening</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>Prior to treating patients with lisdexamfetamine dimesylate capsules, assess: </paragraph>
                        <list>
                           <item>
                              <content styleCode="xmChange"/>for the presence ofcardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia,andphysical exam) <content styleCode="italics">[seeWarnings and Precautions (<linkHtml href="#_6dc62472-9038-1776-e43e-30fa4c123dd3">5.2</linkHtml>)]</content>.</item>
                           <item>
                              <content styleCode="xmChange"/>the family history and clinically evaluate patients for motor or verbal tics or Tourettes syndrome before initiating lisdexamfetamine dimesylate capsules<content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_7b73ed51-becd-2633-4ae4-e99d70d6df6b">5.8</linkHtml>)]. </content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20231220"/>
                  </section>
               </component>
               <component>
                  <section ID="_84b0066f-fad5-120f-e954-9929b2b53b22">
                     <id root="f5eb3c10-8a64-226b-3120-b52a612b27d1"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.2 General Administration Information</title>
                     <text>
                        <paragraph>Take lisdexamfetamine dimesylate capsules orally in the morning with or without food; avoid afternoon doses because ofthepotentialforinsomnia.Lisdexamfetamine dimesylate capsulesmaybeadministeredinoneofthefollowingways:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Informationforlisdexamfetamine dimesylatecapsules:</content>
                        </paragraph>
                        <list>
                           <item>Swallowlisdexamfetamine dimesylatecapsules whole,or </item>
                           <item>Open capsules, empty and mix the entire contents with yogurt, water, or orange juice. Ifthecontentsofthecapsule includeanycompactedpowder,aspoon maybeused tobreakapart the powder. The contents should be mixed until completely dispersed.Consumethe entire mixture immediately.It should not be stored.The active ingredient dissolvescompletely once dispersed; however, a film containing the inactive ingredients mayremaininthe glass orcontainer oncethe mixtureis consumed.</item>
                        </list>
                        <paragraph>Lisdexamfetamine dimesylatecapsules can be substituted with VYVANSE chewable tablets on a unit per unit/mg per mg basis (for example, 30 mg capsules for 30 mg chewable tablet) <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Do not take anything less than one capsule or chewable tablet per day.A single dose should notbe divided.</paragraph>
                     </text>
                     <effectiveTime value="20231102"/>
                  </section>
               </component>
               <component>
                  <section ID="_4f777e54-bf46-3e4b-45cc-e898bda0c446">
                     <id root="8a97b3dd-e4b7-908a-c472-76e5fd984f0a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.3 Dosage for Treatment of ADHD</title>
                     <text>
                        <paragraph>The recommended starting dosage in adults and pediatric patients 6 years and older is 30 mgonce daily in the morning.Dosage may be adjusted in increments of 10 mg or 20 mg atapproximately weekly intervals up to maximum recommended dosage of 70 mg once daily <content styleCode="italics">[seeClinicalStudies (<linkHtml href="#_bab39eaf-3540-8541-210f-5c88ca1ef1bb">14.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220130"/>
                  </section>
               </component>
               <component>
                  <section ID="_565b71d1-35fb-4d11-bbe3-3da0074577af">
                     <id root="61efbf30-bddf-ec4b-f0f5-ae3558c88b68"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.4 Dosage for Treatment of Moderate to Severe BED in Adults</title>
                     <text>
                        <paragraph>The recommended starting dosage in adults is 30 mg once daily to be titrated in increments of 20 mg at approximately weekly intervals to achieve the recommended target dose of 50 mg to 70mg once daily. The maximum recommended dosage is 70 mg once daily <content styleCode="italics">[see Clinical Studies(<linkHtml href="#_ce13a1ec-8b23-c88d-70c0-b8a8197151dd">14.2</linkHtml>)]</content>.Discontinue lisdexamfetamine dimesylate capsulesifbinge eating does not improve.</paragraph>
                     </text>
                     <effectiveTime value="20220130"/>
                  </section>
               </component>
               <component>
                  <section ID="_fd14dd65-3a19-d2b1-98e7-4073315ba37d">
                     <id root="d5d33766-8953-e715-a390-30b6b6e5b834"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.5 Dosage in Patients with Renal Impairment</title>
                     <text>
                        <paragraph>In patients with severe renal impairment (GFR 15 to &lt; 30 mL/min/1.73 m<sup>2</sup>), the maximumdosage should not exceed 50 mg once daily.In patients with end stage renal disease (ESRD,GFR&lt;15mL/min/1.73m<sup>2</sup>),themaximum recommendeddosageis30mgoncedaily <content styleCode="italics">[seeUseinSpecific Populations (<linkHtml href="#_9165f0d1-8ca0-b7fa-837a-310709bb0a8b">8.6</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220130"/>
                  </section>
               </component>
               <component>
                  <section ID="_52cd86a4-c977-4415-dcd9-fd65cc7a024d">
                     <id root="de43ea55-db12-ccdb-4876-dd2acb0511d1"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.6 Dosage Modifications due to Drug Interactions</title>
                     <text>
                        <paragraph>Agentsthatalterurinary pHcanimpacturinaryexcretionandalterblood levelsofamphetamine.Acidifying agents (e.g., ascorbic acid) decrease blood levels, while alkalinizing agents (e.g.,sodium bicarbonate) increase blood levels.Adjust lisdexamfetamine dimesylate capsules dosage accordingly <content styleCode="italics">[see DrugInteractions(<linkHtml href="#_c2819f90-ae45-bce8-0cb9-c2f27b0dfc35">7.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220130"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="DOSAGE_FORMS_AND_STRENGTHS">
               <id root="a0a9dba6-3e2c-6eaf-0b4b-4c8692f41eba"/>
               <code code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>
                     <content styleCode="italics">Lisdexamfetaminedimesylatecapsules:</content>
                  </paragraph>
                  <list>
                     <item>Capsules10mg:Hard gelatin capsule with EEC pink opaque body and EEC pink opaque cap. Imprinted APO L10 in black ink. White to off-white granular fill.</item>
                     <item>Capsules20mg:Hard gelatin capsule with ivory opaque body and ivory opaque cap. Imprinted APO L20 in black ink. White to off-white granular fill.</item>
                     <item>Capsules 30mg:Hard gelatin capsule with white opaque body and orange opaque cap. Imprinted APO L30 in black ink. White to off-white granular fill.</item>
                     <item>Capsules40mg:Hard gelatin capsule with white opaque body and dark green opaque cap. Imprinted APO L40 in black ink. White to off-white granular fill.</item>
                     <item>Capsules50mg:Hard gelatin capsule with white opaque body and light blue opaque cap. Imprinted APO L50 in black ink. White to off-white granular fill.</item>
                     <item>Capsules60mg:Hard gelatin capsule with aqua blue opaque body and aqua blue opaque cap. Imprinted APO L60 in black ink. White to off-white granular fill.</item>
                     <item>Capsules70mg:Hard gelatin capsule with light blue opaque body and medium orange opaque cap. Imprinted APO L70 in black ink. White to off-white granular fill.</item>
                  </list>
               </text>
               <effectiveTime value="20220125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Capsules:10mg,20mg,30mg,40mg,50mg,60mg,70mg(<linkHtml href="#DOSAGE_FORMS_AND_STRENGTHS">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="CONTRAINDICATIONS">
               <id root="873e073e-2a72-ea22-cd90-4052d406a11d"/>
               <code code="34070-3" displayName="CONTRAINDICATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Lisdexamfetamine dimesylate capsulesarecontraindicatedinpatientswith:</paragraph>
                  <list>
                     <item>Known hypersensitivity to amphetamine products or other ingredients of lisdexamfetamine dimesylate capsules.Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have beenobservedinpostmarketing reports <content styleCode="italics">[seeAdverseReactions(<linkHtml href="#_b3ceba1d-fa35-c569-d672-b874c3b66db8">6.2</linkHtml>)]</content>.</item>
                     <item>Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stoppingMAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_b4410b38-5581-fcb5-39b3-9c4b0f013528">5.7</linkHtml>) and DrugInteractions(<linkHtml href="#_c2819f90-ae45-bce8-0cb9-c2f27b0dfc35">7.1</linkHtml>)]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20231117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>Knownhypersensitivitytoamphetamineproducts orotheringredientsinlisdexamfetamine dimesylate capsules(<linkHtml href="#CONTRAINDICATIONS">4</linkHtml>)</item>
                           <item>Use with monoamine oxidase (MAO) inhibitor, or within 14 days of thelastMAOinhibitordose(<linkHtml href="#CONTRAINDICATIONS">4</linkHtml>,<linkHtml href="#_c2819f90-ae45-bce8-0cb9-c2f27b0dfc35">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="WARNINGS_AND_PRECAUTIONS">
               <id root="d10697b4-1794-64f3-59b7-1406f937333b"/>
               <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20220125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>
                              <content styleCode="italics">Risks to Patients with Serious Cardiac Disease: </content>Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease (<linkHtml href="#_6dc62472-9038-1776-e43e-30fa4c123dd3">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Increased Blood Pressure and Heart Rate:</content>Monitor blood pressure andpulse.(<linkHtml href="#OVERDOSAGE">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Psychiatric Adverse Reactions:</content>Prior to initiating lisdexamfetamine dimesylate capsules, screen patients for risk factors for developing a manic episode. If new psychotic or manic symptoms occur, consider discontinuing lisdexamfetamine dimesylate capsules.(<linkHtml href="#_b4410b38-5581-fcb5-39b3-9c4b0f013528">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Long-Term Suppression of Growth in Pediatric Patients:</content>Closely monitor growth (height and weight) in pediatric patients. Pediatric patients not growing or gaining height or weight as expected may need to have their treatment interrupted. (<linkHtml href="#CONTRAINDICATIONS">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">PeripheralVasculopathy,includingRaynaudsphenomenon:</content>Careful observation for digital changes is necessary during lisdexamfetamine dimesylate capsules treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for patients who develop signs or symptoms of peripheral vasculopathy.(<linkHtml href="#_55b8f6eb-b923-8986-ec3f-cf5561192d43">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Serotonin Syndrome:</content>Increased risk when co-administered with serotonergicagents(e.g., SSRIs, SNRIs, triptans),but alsoduringoverdosage situations.If it occurs, discontinue lisdexamfetamine dimesylate capsules and initiate supportive treatment (<linkHtml href="#_d2108e06-f1e5-9e1a-86a2-59273bf634b1">4</linkHtml>, <linkHtml href="#_05b1693a-479c-425e-2e57-26a72f39fe27">5.7</linkHtml>,<linkHtml href="#_889fcaf4-adff-dea8-4a22-0b65ea3c99f9">10</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Motor and Verbal Tics, and Worsening of Tourettes Syndrome:</content> Before initiating lisdexamfetamine dimesylate capsules, assess the family history and clinically evaluate patients for tics or Tourettes syndrome. Regularly monitor patients for the emergence or worsening of tics or Tourettes syndrome. Discontinue treatment if clinically appropriate. (<linkHtml href="#_7b73ed51-becd-2633-4ae4-e99d70d6df6b">5.8</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_1c87c681-652b-26d1-f5e9-c4bcf6a09df7">
                     <id root="02648994-3b14-af59-ca1c-ca3d719972e6"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>
                        <content styleCode="xmChange"/>5.1 Abuse, Misuse, and Addiction</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>Lisdexamfetamine dimesylate capsules has a high potential for abuse and misuse. The use of lisdexamfetamine dimesylate capsules exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Lisdexamfetamine dimesylate capsules can be diverted for non-medical use into illicit channels or distribution <content styleCode="italics">[see Drug Abuse and Dependence (<linkHtml href="#ABUSE">9.2</linkHtml>)</content>
                           <content styleCode="italics">]</content>. Misuse and abuse of CNS stimulants, including lisdexamfetamine dimesylate capsules, can result in overdose and death <content styleCode="italics">[see Overdosage (<linkHtml href="#OVERDOSAGE">10</linkHtml>)]</content>, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.  </paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>    Before prescribing lisdexamfetamine dimesylate capsules, assess each patients risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store lisdexamfetamine dimesylate capsules in a safe place, preferably locked, and instruct patients to not give lisdexamfetamine dimesylate capsules to anyone else. Throughout lisdexamfetamine dimesylate capsules treatment, reassess each patients risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.</paragraph>
                     </text>
                     <effectiveTime value="20231102"/>
                  </section>
               </component>
               <component>
                  <section ID="_6dc62472-9038-1776-e43e-30fa4c123dd3">
                     <id root="6a905f99-53d3-c585-4dcc-a961a5415acb"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>
                        <content styleCode="xmChange"/>5.2 Risks to Patients with Serious Cardiac Disease</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at the recommended ADHD dosage. Avoid lisdexamfetamine dimesylate capsules use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease.   </paragraph>
                     </text>
                     <effectiveTime value="20231102"/>
                  </section>
               </component>
               <component>
                  <section ID="_889fcaf4-adff-dea8-4a22-0b65ea3c99f9">
                     <id root="2282f7a3-18ef-93d2-c4be-ee4eb20e1818"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.3 Increased Blood Pressure and Heart Rate</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>CNS stimulants cause an increase in blood pressure (mean increase about 2 to 4 mm Hg) andheart rate (mean increase about 3 to 6 bpm). Some patients may have larger increases.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>Monitor all lisdexamfetamine dimesylate-treated patients for potential tachycardia andhypertension.</paragraph>
                     </text>
                     <effectiveTime value="20231102"/>
                  </section>
               </component>
               <component>
                  <section ID="_05b1693a-479c-425e-2e57-26a72f39fe27">
                     <id root="b6937045-9aab-bdbb-4b8b-c3143f945882"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.4 Psychiatric Adverse Reactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">ExacerbationofPre-existingPsychosis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder inpatientswith a pre-existing psychotic disorder.</paragraph>
                        <paragraph>
                           <content styleCode="underline">InductionofaManicEpisodeinPatientswithBipolarDisorder</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>
                           <content styleCode="xmChange"/>CNS stimulants may induce a manic or mixed episode. Prior to initiating lisdexamfetamine dimesylate capsules treatment,screen patients for risk factors for developing a manic episode (e.g.,comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, anddepression).</paragraph>
                        <paragraph>
                           <content styleCode="underline">NewPsychoticorManicSymptoms</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>CNS stimulants, at the recommended dosage, may cause psychotic or manic symptoms (e.g.,hallucinations, delusional thinking, or mania) in patients without a prior history of psychoticillness or mania. In a pooledanalysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic ormanic symptoms occurred in approximately 0.1% of CNS stimulant-treated patients compared to 0% ofplacebo-treatedpatients. If such symptoms occur, consider discontinuing lisdexamfetamine dimesylate capsules.</paragraph>
                     </text>
                     <effectiveTime value="20231117"/>
                  </section>
               </component>
               <component>
                  <section ID="_d2108e06-f1e5-9e1a-86a2-59273bf634b1">
                     <id root="998b9157-f325-3a17-82a4-c881498f940b"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.5 Long-Term Suppression of Growth in Pediatric Patients</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>CNS stimulants have been associated with weight loss and slowing of growth rate in pediatricpatients.</paragraph>
                        <paragraph>In a 4-week, placebo-controlled trial of lisdexamfetamine dimesylate capsules inpediatric patients ages 6 to 12 years old with ADHD, there was a dose-related decrease in weight in the lisdexamfetamine dimesylate  groups compared to weight gain in the placebo group.Additionally, in studies ofanother stimulant,therewasslowingoftheincrease inheight<content styleCode="italics">[seeAdverse Reactions(<linkHtml href="#_f375ae39-09ae-27ca-d7c4-830c835a13a0">6.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>
                           <content styleCode="none">Closely monitor growth (weight and height) in lisdexamfetamine dimesylate-treated pediatric patients. Patients who are not growing or gaining height or weight as expected may need to have theirtreatment interrupted. Lisdexamfetamine dimesylate capsules are not approved for use in pediatric patients below 6 years ofage</content><content styleCode="italics">[see Use in SpecificPopulations(<linkHtml href="#PEDIATRIC_USE">8.4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231117"/>
                  </section>
               </component>
               <component>
                  <section ID="_55b8f6eb-b923-8986-ec3f-cf5561192d43">
                     <id root="ec5365a3-5ae0-645a-6622-18028dd65995"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.6 Peripheral Vasculopathy, including Raynaud's Phenomenon</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>CNS stimulants,including lisdexamfetamine dimesylate capsules, used to treat ADHD areassociatedwithperipheralvasculopathy,includingRaynauds phenomenon.Signs and symptoms are usually intermittent and mild; however, sequelae have included digital ulceration and/or soft tissue breakdown.Effects of peripheralvasculopathy, including Raynauds phenomenon, were observed in post-marketing reports and at the therapeutic dosages of CNS stimulantsinallagegroupsthroughoutthecourseoftreatment.Signs and symptoms generally improved after dosage reductionor discontinuation of the CNS stimulant. </paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>Carefulobservation for digital changes is necessary during lisdexamfetamine dimesylate treatment. Further clinicalevaluation(e.g., rheumatologyreferral)maybe appropriateforlisdexamfetamine dimesylate-treated patients who develop signs or symptoms of peripheral vasculopathy. </paragraph>
                     </text>
                     <effectiveTime value="20231117"/>
                  </section>
               </component>
               <component>
                  <section ID="_b4410b38-5581-fcb5-39b3-9c4b0f013528">
                     <id root="26e6f030-8b86-b1c6-61d6-9a4bf062cd98"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.7 Serotonin Syndrome</title>
                     <text>
                        <paragraph>Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines areusedincombinationwithotherdrugsthataffect theserotonergicneurotransmittersystemssuchasmonoamine oxidaseinhibitors(MAOIs), selectiveserotoninreuptake inhibitors(SSRIs),serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium,tramadol, tryptophan, buspirone, and St. Johns Wort <content styleCode="italics">[see Drug Interactions (<linkHtml href="#_c2819f90-ae45-bce8-0cb9-c2f27b0dfc35">7.1</linkHtml>)]</content>. The co-administration with cytochrome P450 2D6 (CYP2D6) inhibitors may also increase the risk withincreased exposuretotheactivemetaboliteoflisdexamfetamine dimesylate capsules(dextroamphetamine).Inthesesituations,consideranalternativenon-serotonergicdrugoranalternativedrugthatdoesnotinhibit CYP2D6 <content styleCode="italics">[see Drug Interactions(<linkHtml href="#_c2819f90-ae45-bce8-0cb9-c2f27b0dfc35">7.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations,delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness,diaphoresis,flushing,hyperthermia),neuromuscularsymptoms(e.g.,tremor, rigidity,myoclonus,hyperreflexia,incoordination),seizures,and/or gastrointestinalsymptoms(e.g.,nausea,vomiting, diarrhea).</paragraph>
                        <paragraph>Concomitantuseoflisdexamfetamine dimesylate capsuleswithMAOIdrugs iscontraindicated<content styleCode="italics">[seeContraindications(<linkHtml href="#CONTRAINDICATIONS">4</linkHtml>)]</content>.</paragraph>
                        <paragraph>Discontinue treatment with lisdexamfetamine dimesylate capsules and any concomitant serotonergic agents immediately ifsymptomsofserotoninsyndrome occur,andinitiate supportivesymptomatictreatment.Ifconcomitant use of lisdexamfetamine dimesylate capsules with other serotonergic drugs or CYP2D6 inhibitors is clinicallywarranted, initiate lisdexamfetamine dimesylate capsules with lower doses, monitor patients for the emergence of serotonin syndromeduringdruginitiationortitration,andinformpatients oftheincreasedriskforserotonin syndrome.</paragraph>
                     </text>
                     <effectiveTime value="20231117"/>
                  </section>
               </component>
               <component>
                  <section ID="_7b73ed51-becd-2633-4ae4-e99d70d6df6b">
                     <id root="8a8ca618-cf4b-119b-c9d3-0a5cd42266bc"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.8 Motor and Verbal Tics, and Worsening of Tourette's Syndrome</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>CNS stimulants, including amphetamine, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourettes syndrome has also been reported <content styleCode="italics">[see Adverse Reactions (6.2)]. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>Before initiating lisdexamfetamine dimesylate capsules, assess the family history and clinically evaluate patients for tics or Tourettes syndrome. Regularly monitor lisdexamfetamine dimesylate -treated patients for the emergence or worsening of tics or Tourettes syndrome, and discontinue treatment if clinically appropriate.  </paragraph>
                     </text>
                     <effectiveTime value="20231106"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ADVERSE_REACTIONS">
               <id root="2431c80f-14ad-b61d-e5b0-d69a2fe255f7"/>
               <code code="34084-4" displayName="ADVERSE REACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Thefollowingadversereactionsarediscussedingreaterdetail inothersections ofthelabeling:</paragraph>
                  <list>
                     <item>Knownhypersensitivitytoamphetamineproductsorotheringredientsoflisdexamfetamine dimesylate capsules <content styleCode="italics">[seeContraindications(<linkHtml href="#CONTRAINDICATIONS">4</linkHtml>)]</content>
                     </item>
                     <item>HypertensiveCrisis WhenUsedConcomitantlywithMonoamineOxidase Inhibitors<content styleCode="italics">[seeContraindications(<linkHtml href="#CONTRAINDICATIONS">4</linkHtml>) and Drug Interactions(<linkHtml href="#_c2819f90-ae45-bce8-0cb9-c2f27b0dfc35">7.1</linkHtml>)]</content>
                     </item>
                     <item>Abuse, Misuse, and Addiction <content styleCode="italics">[see Boxed Warning, Warnings and Precautions (<linkHtml href="#_1c87c681-652b-26d1-f5e9-c4bcf6a09df7">5.1</linkHtml>), and DrugAbuseand Dependence(<linkHtml href="#ABUSE">9.2</linkHtml>, <linkHtml href="#DEPENDENCE"> 9.3</linkHtml>)]</content>
                     </item>
                     <item>Risks to Patients with Serious Cardiac Disease<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_6dc62472-9038-1776-e43e-30fa4c123dd3">5.2</linkHtml>)]</content>
                     </item>
                     <item>Increased BloodPressureandHeart Rate<content styleCode="italics">[seeWarnings andPrecautions(<linkHtml href="#_889fcaf4-adff-dea8-4a22-0b65ea3c99f9">5.3</linkHtml>)]</content>
                     </item>
                     <item>PsychiatricAdverse Reactions<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_05b1693a-479c-425e-2e57-26a72f39fe27">5.4</linkHtml>)]</content>
                     </item>
                     <item>Long-Term SuppressionofGrowth in Pediatric Patients<content styleCode="italics">[seeWarnings andPrecautions(<linkHtml href="#_d2108e06-f1e5-9e1a-86a2-59273bf634b1">5.5</linkHtml>)]</content>
                     </item>
                     <item>PeripheralVasculopathy,includingRaynaudsphenomenon<content styleCode="italics">[seeWarnings andPrecautions(<linkHtml href="#_55b8f6eb-b923-8986-ec3f-cf5561192d43">5.6</linkHtml>)]</content>
                     </item>
                     <item>SerotoninSyndrome <content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_b4410b38-5581-fcb5-39b3-9c4b0f013528">5.7</linkHtml>)]</content>
                     </item>
                     <item>Motor and Verbal Tics, and Worsening of Tourettes Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_7b73ed51-becd-2633-4ae4-e99d70d6df6b">5.8</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20231117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence 5% and at a rate at least twiceplacebo)inpediatricpatientsages6to17years,and/or adultswithADHDwereanorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth,irritability,insomnia, nausea,upperabdominal pain,andvomiting (<linkHtml href="#_f375ae39-09ae-27ca-d7c4-830c835a13a0">6.1</linkHtml>)</paragraph>
                        <paragraph>Most common adverse reactions (incidence  5% and at a rate at least twiceplacebo) in adults with BED were dry mouth, insomnia, decreased appetite,increasedheart rate,constipation,feeling jittery,and anxiety(<linkHtml href="#_f375ae39-09ae-27ca-d7c4-830c835a13a0">6.1</linkHtml>)<content styleCode="bold"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_f375ae39-09ae-27ca-d7c4-830c835a13a0">
                     <id root="45edcc83-8d53-5635-803f-ade555718f54"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction ratesobserved in the clinical trials of a drug cannot be directly compared to rates in the clinical trialsofanother drug and maynot reflect the rates observedin practice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">AttentionDeficit HyperactivityDisorder</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>The safety data in this section is based on data from the 4-week controlled parallel-group clinicalstudiesoflisdexamfetamine dimesylate capsulesinpediatricandadultpatients withADHD <content styleCode="italics">[seeClinicalStudies (<linkHtml href="#_bab39eaf-3540-8541-210f-5c88ca1ef1bb">14.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Adverse Reactions Associated with Discontinuation of Treatment in ADHD Clinical Trials</content></paragraph>
                        <paragraph>In the controlled trial in pediatric patients ages 6 to 12 years (Study 1), 8% (18/218) oflisdexamfetamine dimesylate-treatedpatientsdiscontinuedduetoadverse reactionscomparedto0%(0/72)of placebo-treated patients.The most frequently reported adverse reactions (1% or more and twice rate of placebo) were ECG voltage criteria for ventricular hypertrophy, tic, vomiting,psychomotor hyperactivity, insomnia, decreased appetite and rash [2 instances for each adversereaction, i.e., 2/218 (1%)].Less frequently reported adverse reactions (less than 1% or less than twice rate of placebo) included abdominal pain upper, dry mouth, weight decreased, dizziness, somnolence,logorrhea, chest pain, anger and hypertension.</paragraph>
                        <paragraph>In the controlled trial in pediatric patients ages 13 to 17 years (Study 4), 3% (7/233) oflisdexamfetamine dimesylate-treated patients discontinued due to adverse reactions compared to 1% (1/77) ofplacebo-treated patients.The most frequently reported adverse reactions (1% or more and twice rate of placebo) were decreased appetite (2/233; 1%) and insomnia (2/233; 1%).Less frequentlyreported adverse reactions (less than 1% or less than twice rate of placebo) included irritability,dermatillomania,moodswings, and dyspnea.</paragraph>
                        <paragraph>In the controlled adult trial (Study 7), 6% (21/358) of lisdexamfetamine dimesylate-treated patients discontinuedduetoadversereactions comparedto2%(1/62)ofplacebo-treatedpatients.Themostfrequently reported adverse reactions (1% or more and twice rate of placebo) were insomnia (8/358; 2%),tachycardia (3/358; 1%), irritability (2/358; 1%), hypertension (4/358; 1%), headache (2/358;1%), anxiety (2/358; 1%), and dyspnea (3/358; 1%).Less frequently reported adverse reactions(less than 1% or less than twice rate of placebo) included palpitations, diarrhea, nausea,decreasedappetite, dizziness,agitation, depression,paranoia and restlessness.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Adverse Reactions Occurring at an Incidence of 5% or More Among Lisdexamfetamine Dimesylate Capsules Treated Patientswith ADHDinClinical Trials</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>The most common adverse reactions (incidence 5% and at a rate at least twice placebo)reported in pediatric patients ages 6 to 17 years, and/or adults were anorexia, anxiety, decreasedappetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upperabdominal pain, and vomiting.</paragraph>
                        <paragraph>
                           <content styleCode="italics">AdverseReactions OccurringatanIncidenceof 2%orMoreAmongLisdexamfetamine Dimesylate CapsulesTreatedPatientswith ADHD in Clinical Trials</content>
                        </paragraph>
                        <paragraph>Adverse reactions reported in the controlled trials in pediatric patients ages, 6 to 12 years (Study1), pediatric patients ages 13 to 17 years (Study 4), and adult patients (Study 7) treated withlisdexamfetamine dimesylate capsules or placebo are presentedinTables 1,2 and 3 below.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table1 Adverse Reactions Reported by 2% or More of Pediatric Patients Ages 6 to12 Years with ADHD Taking Lisdexamfetamine Dimesylate Capsules and Greater than or Equal toTwice the Incidence in Patients Taking Placebo in a 4-Week Clinical Trial(Study1)</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody align="center">
                              <tr>
                                 <td/>
                                 <td align="center">
                                    <content styleCode="bold">Lisdexamfetamine Dimesylate Capsules <br/>(n=218)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo <br/>(n=72)</content>
                                 </td>
                              </tr>
                              <tr align="center">
                                 <td> DecreasedAppetite </td>
                                 <td> 39% </td>
                                 <td> 4% </td>
                              </tr>
                              <tr align="center">
                                 <td> Insomnia </td>
                                 <td> 22% </td>
                                 <td> 3% </td>
                              </tr>
                              <tr>
                                 <td> AbdominalPain Upper </td>
                                 <td> 12% </td>
                                 <td> 6% </td>
                              </tr>
                              <tr>
                                 <td> Irritability </td>
                                 <td> 10% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Vomiting </td>
                                 <td> 9% </td>
                                 <td> 4% </td>
                              </tr>
                              <tr>
                                 <td> WeightDecreased </td>
                                 <td> 9% </td>
                                 <td> 1% </td>
                              </tr>
                              <tr>
                                 <td> Nausea </td>
                                 <td> 6% </td>
                                 <td> 3% </td>
                              </tr>
                              <tr>
                                 <td> DryMouth </td>
                                 <td> 5% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Dizziness </td>
                                 <td> 5% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Affect lability </td>
                                 <td> 3% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Rash </td>
                                 <td> 3% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Pyrexia </td>
                                 <td> 2% </td>
                                 <td> 1% </td>
                              </tr>
                              <tr>
                                 <td> Somnolence </td>
                                 <td> 2% </td>
                                 <td> 1% </td>
                              </tr>
                              <tr>
                                 <td> Tic </td>
                                 <td> 2% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Anorexia </td>
                                 <td> 2% </td>
                                 <td> 0% </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Table2 Adverse Reactions Reported by 2% or More of Pediatric Patients Ages 13 to17 Years with ADHD Taking Lisdexamfetamine Dimesylate Capsules and Greater than or Equal toTwice the Incidence in Patients Taking Placebo in a 4-Week Clinical Trial(Study4)</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody align="center">
                              <tr>
                                 <td>  </td>
                                 <td>
                                    <content styleCode="bold">Lisdexamfetamine Dimesylate Capsules </content>
                                    <content styleCode="bold">
                                       <br/>(n=233)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">(n=77)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td> DecreasedAppetite </td>
                                 <td> 34% </td>
                                 <td> 3% </td>
                              </tr>
                              <tr>
                                 <td> Insomnia </td>
                                 <td> 13% </td>
                                 <td> 4% </td>
                              </tr>
                              <tr>
                                 <td> Weight Decreased </td>
                                 <td> 9% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> DryMouth </td>
                                 <td> 4% </td>
                                 <td> 1% </td>
                              </tr>
                              <tr>
                                 <td> Palpitations </td>
                                 <td> 2% </td>
                                 <td> 1% </td>
                              </tr>
                              <tr>
                                 <td> Anorexia </td>
                                 <td> 2% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Tremor </td>
                                 <td> 2% </td>
                                 <td> 0% </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Table3 Adverse Reactions Reported by 2% or More of Adult Patients with ADHDTaking Lisdexamfetamine Dimesylate Capsules and Greater than or Equal to Twice the Incidence inPatientsTaking Placebo ina 4-WeekClinical Trial(Study 7)</content>
                        </paragraph>
                        <table frame="border" rules="all">
                           <tbody align="center">
                              <tr>
                                 <td>  </td>
                                 <td>
                                    <content styleCode="bold">Lisdexamfetamine Dimesylate Capsules <br/>(n=358)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo</content>
                                    <content styleCode="bold">
                                       <br/>(n=62)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td> DecreasedAppetite </td>
                                 <td> 27% </td>
                                 <td> 2% </td>
                              </tr>
                              <tr>
                                 <td> Insomnia </td>
                                 <td> 27% </td>
                                 <td> 8% </td>
                              </tr>
                              <tr>
                                 <td> DryMouth </td>
                                 <td> 26% </td>
                                 <td> 3% </td>
                              </tr>
                              <tr>
                                 <td> Diarrhea </td>
                                 <td> 7% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Nausea </td>
                                 <td> 7% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Anxiety </td>
                                 <td> 6% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Anorexia </td>
                                 <td> 5% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> FeelingJittery </td>
                                 <td> 4% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Agitation </td>
                                 <td> 3% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> IncreasedBloodPressure </td>
                                 <td> 3% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Hyperhidrosis </td>
                                 <td> 3% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Restlessness </td>
                                 <td> 3% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> DecreasedWeight </td>
                                 <td> 3% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Dyspnea </td>
                                 <td> 2% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> IncreasedHeart Rate </td>
                                 <td> 2% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Tremor </td>
                                 <td> 2% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Palpitations </td>
                                 <td> 2% </td>
                                 <td> 0% </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In addition, in the adult population erectile dysfunction was observed in 2.6% of males onlisdexamfetamine dimesylate capsulesand0%onplacebo;decreased libidowasobserved in1.4%ofsubjectsonlisdexamfetamine dimesylate capsules and0% on placebo.</paragraph>
                        <paragraph>
                           <content styleCode="italics">WeightLossandSlowing GrowthRateinPediatricPatients withADHD</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>In a controlled trial of lisdexamfetamine dimesylate capsules in pediatric patients ages 6 to 12 years (Study 1), mean weightloss from baseline after 4 weeks of therapy was -0.9, -1.9, and -2.5 pounds, respectively, forpatients receiving 30 mg, 50 mg, and 70 mg of lisdexamfetamine dimesylate capsules, compared to a 1 pound weight gainfor patients receiving placebo.Higher doses were associated with greater weight loss with 4weeks of treatment.Careful follow-up for weight in pediatric patients ages 6 to 12 years whoreceived lisdexamfetamine dimesylate capsules over 12 months suggests that consistently medicated pediatric patients (i.e.,treatment for 7 days per week throughout the year) have a slowing in growth rate, measured bybody weight as demonstrated by an age- and sex-normalized mean change from baseline inpercentile, of -13.4 over 1 year (average percentiles at baseline and 12 months were 60.9 and47.2, respectively).In a 4-week controlled trial of lisdexamfetamine dimesylate capsules in pediatric patients ages 13 to 17 years, mean weight loss from baseline to endpoint was -2.7, -4.3, and -4.8 lbs., respectively, forpatients receiving30mg,50mg,and70mgoflisdexamfetamine dimesylate capsules,comparedtoa2poundweightgainfor patients receiving placebo.</paragraph>
                        <paragraph>Careful follow-up of weight and height in pediatric patients ages 7 to 10 years who wererandomized to either methylphenidate or non-medication treatment groups over 14 months, aswell asinnaturalisticsubgroupsofnewlymethylphenidate-treatedandnon-medicationtreated pediatric patients over 36 months (to the ages of 10 to 13 years), suggests that consistentlymedicated pediatricpatientsages7to13years(i.e.,treatmentfor7daysperweekthroughoutthe year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth inheight and2.7kglessgrowthinweightover3years), withoutevidence ofgrowthreboundduring this period of development.In a controlled trial of amphetamine (d- to l-enantiomer ratioof 3:1) in pediatric patients ages 13 to 17 years, mean weight change from baseline within theinitial 4weeksof therapywas-1.1 poundsand-2.8 pounds,respectively,forpatientsreceiving10 mg and 20 mg of amphetamine. Higher doses were associated with greater weight loss within theinitial 4weeks oftreatment <content styleCode="italics">[seeWarnings andPrecautions (<linkHtml href="#_d2108e06-f1e5-9e1a-86a2-59273bf634b1">5.5</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">WeightLossinAdults withADHD</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>Inthecontrolledadulttrial(Study 7),meanweight lossafter4weeksoftherapywas2.8pounds, 3.1 pounds, and 4.3 pounds, for patients receiving final doses of 30 mg, 50 mg, and 70 mg oflisdexamfetamine dimesylate capsules,respectively,comparedtoameanweight gainof0.5poundsforpatientsreceiving placebo.</paragraph>
                        <paragraph>
                           <content styleCode="underline">BingeEatingDisorder</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>The safety data in this section is based on data from two 12-week parallel group, flexible-dose,placebo-controlled studies in adults with BED [<content styleCode="italics">see Clinical Studies <linkHtml href="#_ce13a1ec-8b23-c88d-70c0-b8a8197151dd">14.2</linkHtml>]</content>.Patients withcardiovascularrisk factors otherthanobesity andsmoking were excluded.</paragraph>
                        <paragraph>
                           <content styleCode="italics">AdverseReactions AssociatedwithDiscontinuationofTreatmentinBEDClinical Trials</content>
                        </paragraph>
                        <paragraph>In controlled trials of patients ages 18 to 55 years, 5.1% (19/373) of lisdexamfetamine dimesylate-treated patientsdiscontinued due to adverse reactions compared to 2.4% (9/372) of placebo-treated patients.Nosingleadverse reactionledtodiscontinuationin1%ormoreoflisdexamfetamine dimesylate-treatedpatients.</paragraph>
                        <paragraph>Lesscommonly reportedadversereactions(lessthan1%orlessthantwice rateofplacebo) included increased heart rate, headache, abdominal pain upper, dyspnea, rash, insomnia,irritability,feeling jitteryand anxiety.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Adverse Reactions Occurring at an Incidence of5% or More and At Least Twice PlaceboAmongLisdexamfetamine Dimesylate CapsulesTreated Patientswith BEDin Clinical Trials</content>
                           <content styleCode="italics"/>
                        </paragraph>
                        <paragraph>Themostcommonadverse reactions(incidence5%andatarateatleasttwiceplacebo) reported in adults were dry mouth, insomnia, decreased appetite, increased heart rate,constipation,feeling jittery, and anxiety.</paragraph>
                        <paragraph>
                           <content styleCode="bold"/>
                           <content styleCode="italics">Adverse Reactions Occurring at an Incidence of 2% or More and At Least Twice Placebo AmongLisdexamfetamine Dimesylate CapsulesTreated Patients with BEDin Clinical Trials</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>Adversereactions reportedinthepooledcontrolledtrialsinadult patients(Study11and12)treatedwithlisdexamfetamine dimesylate capsulesorplacebo are presentedinTable 4 below.</paragraph>
                        <paragraph>
                           <content styleCode="bold"/>
                           <content styleCode="bold">Table4 Adverse Reactions Reported by 2% or More of Adult Patients with BED Taking Lisdexamfetamine Dimesylate Capsules and Greater than or Equal to Twice the Incidence inPatientsTakingPlacebo in12-WeekClinical Trials(Study11and12)</content>
                        </paragraph>
                        <table frame="border" rules="all">
                           <tbody align="center">
                              <tr>
                                 <td>  </td>
                                 <td>
                                    <content styleCode="bold">Lisdexamfetamine Dimesylate Capsules </content>
                                    <content styleCode="bold">
                                       <br/>(N=373)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo <br/>
                                    </content>
                                    <content styleCode="bold">(N=372)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td> DryMouth </td>
                                 <td> 36% </td>
                                 <td> 7% </td>
                              </tr>
                              <tr>
                                 <td> Insomnia<sup>1</sup>
                                 </td>
                                 <td> 20% </td>
                                 <td> 8% </td>
                              </tr>
                              <tr>
                                 <td> DecreasedAppetite </td>
                                 <td> 8% </td>
                                 <td> 2% </td>
                              </tr>
                              <tr>
                                 <td> IncreasedHeartRate<sup>2</sup>
                                 </td>
                                 <td> 7% </td>
                                 <td> 1% </td>
                              </tr>
                              <tr>
                                 <td> Feeling Jittery </td>
                                 <td> 6% </td>
                                 <td> 1% </td>
                              </tr>
                              <tr>
                                 <td> Constipation </td>
                                 <td> 6% </td>
                                 <td> 1% </td>
                              </tr>
                              <tr>
                                 <td> Anxiety </td>
                                 <td> 5% </td>
                                 <td> 1% </td>
                              </tr>
                              <tr>
                                 <td> Diarrhea </td>
                                 <td> 4% </td>
                                 <td> 2% </td>
                              </tr>
                              <tr>
                                 <td> DecreasedWeight </td>
                                 <td> 4% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Hyperhidrosis </td>
                                 <td> 4% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Vomiting </td>
                                 <td> 2% </td>
                                 <td> 1% </td>
                              </tr>
                              <tr>
                                 <td> Gastroenteritis </td>
                                 <td> 2% </td>
                                 <td> 1% </td>
                              </tr>
                              <tr>
                                 <td> Paresthesia </td>
                                 <td> 2% </td>
                                 <td> 1% </td>
                              </tr>
                              <tr>
                                 <td> Pruritus </td>
                                 <td> 2% </td>
                                 <td> 1% </td>
                              </tr>
                              <tr>
                                 <td> UpperAbdominalPain </td>
                                 <td> 2% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Energy Increased </td>
                                 <td> 2% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Urinary TractInfection </td>
                                 <td> 2% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Nightmare </td>
                                 <td> 2% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> Restlessness </td>
                                 <td> 2% </td>
                                 <td> 0% </td>
                              </tr>
                              <tr>
                                 <td> OropharyngealPain </td>
                                 <td> 2% </td>
                                 <td> 0% </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>1Includesallpreferredtermscontainingthewordinsomnia. <sup/>
                        </paragraph>
                        <paragraph>
                           <sup>2</sup>Includesthepreferredtermsheartrateincreasedandtachycardia.</paragraph>
                        <paragraph>
                           <content styleCode="bold"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231103"/>
                  </section>
               </component>
               <component>
                  <section ID="_b3ceba1d-fa35-c569-d672-b874c3b66db8">
                     <id root="fdd65713-137e-5b78-7a57-5d9ef0eeb046"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of lisdexamfetamine dimesylate capsules.Because these reactions are reported voluntarily from a population of uncertain size, it is notalways possible to reliably estimate their frequency or establish a causal relationship to drugexposure. These events are as follows: cardiomyopathy, mydriasis, diplopia, difficulties withvisualaccommodation,blurredvision,eosinophilichepatitis,anaphylacticreaction, hypersensitivity,dyskinesia,dysgeusia, motor and verbaltics,bruxism,depression,dermatillomania,alopecia,aggression,Stevens-JohnsonSyndrome,chestpain,angioedema,urticaria,seizures,libidochanges,frequent or prolongederections, constipation, rhabdomyolysis, and intestinal ischemia.</paragraph>
                     </text>
                     <effectiveTime value="20231103"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="DRUG_INTERACTIONS">
               <id root="1ae0c716-1b24-b2ab-93c1-465b722724dc"/>
               <code code="34073-7" displayName="DRUG INTERACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20220125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="italics">AcidifyingandAlkalinizingAgents:</content>Agentsthatalterurinary pHcanalterbloodlevels of amphetamine.Acidifying agents decrease amphetamine blood levels,while alkalinizing agents increase amphetamine blood levels.Adjustlisdexamfetamine dimesylate capsulesdosage accordingly (<linkHtml href="#_52cd86a4-c977-4415-dcd9-fd65cc7a024d">2.6</linkHtml>,<linkHtml href="#_09737a21-bf66-556a-efcc-df6b587131f6"> 7.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_c2819f90-ae45-bce8-0cb9-c2f27b0dfc35">
                     <id root="a9e46805-323d-f3f0-e158-734bafd0c9b7"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.1 Drugs Having Clinically Important Interactions with Amphetamines</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Table 5           Drugshaving clinicallyimportantinteractionswithamphetamines.</content>
                        </paragraph>
                        <table frame="border" rules="all">
                           <tbody>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold italics">MAOInhibitors(MAOI)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>   ClinicalImpact   </td>
                                 <td>   MAOIantidepressantsslowamphetaminemetabolism,increasingamphetamineseffect   ontherelease   ofnorepinephrineandothermonoamines from adrenergic nerve endings   causing headaches and othersignsofhypertensivecrisis.   Toxicneurologicaleffects   andmalignanthyperpyrexiacan occur,sometimeswith   fatalresults.   </td>
                              </tr>
                              <tr>
                                 <td>   Intervention   </td>
                                 <td>   Donotadministerlisdexamfetamine dimesylate capsulesduring   orwithin14daysfollowingtheadministrationof MAOI <content styleCode="italics">[seeContraindications(<linkHtml href="#CONTRAINDICATIONS">4</linkHtml>)]</content>.   </td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold italics">SerotonergicDrugs</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>   ClinicalImpact   </td>
                                 <td>   Theconcomitantuseoflisdexamfetamine dimesylate capsulesandserotonergicdrugs   increasestherisk   ofserotonin syndrome.   </td>
                              </tr>
                              <tr>
                                 <td>   Intervention   </td>
                                 <td>   Initiate with lower doses and monitor   patients for signs and symptoms ofserotonin   syndrome, particularly during lisdexamfetamine dimesylate capsules initiation   or dosageincrease. If serotonin   syndrome occurs, discontinue lisdexamfetamine dimesylate capsules and theconcomitantserotonergicdrug(s)<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_b4410b38-5581-fcb5-39b3-9c4b0f013528">5.7</linkHtml>)]</content>.   </td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold italics">CYP2D6Inhibitors</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>   ClinicalImpact   </td>
                                 <td>   The concomitant use of lisdexamfetamine   dimesylate capsules and CYP2D6 inhibitors may increasethe exposure of dextroamphetamine, the active metabolite of lisdexamfetamine   dimesylate capsulescompared to the   use of the drug alone and increase the risk of serotoninsyndrome.   </td>
                              </tr>
                              <tr>
                                 <td>   Intervention   </td>
                                 <td>   Initiate with lower doses and monitor patients for signs and   symptoms ofserotonin syndrome   particularly during lisdexamfetamine dimesylate capsules initiation and after   adosageincrease.Ifserotoninsyndromeoccurs,discontinuelisdexamfetamine dimesylate capsulesand the CYP2D6 inhibitor<content styleCode="italics">[see   WarningsandPrecautions(<linkHtml href="#_b4410b38-5581-fcb5-39b3-9c4b0f013528">5.7</linkHtml>)andOverdosage(<linkHtml href="#OVERDOSAGE">10</linkHtml>)]</content>.   </td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold italics">AlkalinizingAgents</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>   ClinicalImpact   </td>
                                 <td>   Urinaryalkalinizingagentscanincreasebloodlevelsandpotentiatethe   actionof amphetamine.   </td>
                              </tr>
                              <tr>
                                 <td>   Intervention   </td>
                                 <td>   Co-administrationoflisdexamfetamine dimesylate capsulesandurinaryalkalinizingagentsshouldbeavoided.   </td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold italics">AcidifyingAgents</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>   ClinicalImpact   </td>
                                 <td>   Urinaryacidifyingagentscanlower   bloodlevelsand   efficacyofamphetamines.   </td>
                              </tr>
                              <tr>
                                 <td>   Intervention   </td>
                                 <td>   Increasedosebased   onclinicalresponse.   </td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold italics">TricyclicAntidepressants</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>   ClinicalImpact   </td>
                                 <td>   May enhance the activity of tricyclic or   sympathomimetic agents causingstriking   and sustained increases in the concentration of d-amphetamine inthebrain;   cardiovasculareffects canbe potentiated.   </td>
                              </tr>
                              <tr>
                                 <td>   Intervention   </td>
                                 <td>   Monitorfrequentlyandadjustorusealternativetherapybasedonclinicalresponse.   </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220130"/>
                  </section>
               </component>
               <component>
                  <section ID="_ff5903e1-3a62-0361-ab58-b800800195ab">
                     <id root="ac51cc09-e26d-3acd-10cf-f34e180eb539"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.2 Drugs Having No Clinically Important Interactions with Lisdexamfetamine Dimesylate Capsules</title>
                     <text>
                        <paragraph>Froma pharmacokinetic perspective, no dose adjustment oflisdexamfetamine dimesylate capsules are necessary whenlisdexamfetamine dimesylate capsules are co-administered with guanfacine, venlafaxine, or omeprazole. In addition, no doseadjustment of guanfacine or venlafaxine is needed when lisdexamfetamine dimesylate capsules are co-administered <content styleCode="italics">[seeClinical Pharmacology (<linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>Fromapharmacokineticperspective,nodoseadjustmentfordrugsthataresubstratesofCYP1A2(e.g., theophylline,duloxetine,melatonin),CYP2D6(e.g.,atomoxetine,desipramine,venlafaxine),CYP2C19 (e.g.,omeprazole,lansoprazole,clobazam),andCYP3A4(e.g.,midazolam,pimozide,simvastatin)isnecessarywhenlisdexamfetamine dimesylate capsulesareco-administered<content styleCode="italics">[seeClinical Pharmacology(<linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220130"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="USE_IN_SPECIFIC_POPULATIONS">
               <id root="f8f6210f-86ce-52fe-3512-6a13a59b9e9a"/>
               <code code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20220125"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <list>
                           <item>
                              <content styleCode="italics">Pregnancy:</content>Maycausefetal harm(<linkHtml href="#PREGNANCY">8.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Lactation:</content>Breastfeedingnotrecommended(<linkHtml href="#LABOR_AND_DELIVERY">8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="PREGNANCY">
                     <id root="a42cca71-b31e-0bef-9697-81c86885548e"/>
                     <code code="42228-7" displayName="PREGNANCY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Exposure Registry </content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD medications during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychostimulants at 1-866-961-2388 or visiting online at <linkHtml href="#PREGNANCY">https://womensmentalhealth.org/clinical-and%20researchprograms/pregnancyregistry/adhd-medications/</linkHtml>. </paragraph>
                        <paragraph>
                           <content styleCode="underline">RiskSummary</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>Thelimited availabledatafrompublishedliteratureandpostmarketingreports onuseoflisdexamfetamine dimesylate capsules in pregnant women are not sufficient to inform a drug-associated risk for major birthdefects andmiscarriage.Adverse pregnancyoutcomes,including prematuredeliveryandlowbirthweight, have been seen in infants born to mothers dependent on amphetamines [see ClinicalConsiderations].In animal reproduction studies, lisdexamfetamine dimesylate (a prodrug ofd-amphetamine) had no effects on embryo-fetal morphological development or survival whenadministered orally to pregnant rats and rabbits throughout the period of organogenesis.Pre- andpostnatal studies were not conducted with lisdexamfetamine dimesylate.However, amphetamine(d- to l- ratio of 3:1) administration to pregnant rats during gestation and lactation caused adecrease in pup survival and a decrease in pup body weight that correlated with a delay indevelopmentallandmarksatclinicallyrelevant dosesofamphetamine.Inaddition,adverse effectsonreproductiveperformancewereobserved inpupswhosemothersweretreatedwithamphetamine.Long-term neurochemicalandbehavioraleffectshavealsobeenreported inanimaldevelopmentalstudiesusing clinicallyrelevant dosesofamphetamine<content styleCode="italics">[seeData]</content>.</paragraph>
                        <paragraph>Theestimatedbackgroundriskofmajorbirth defectsandmiscarriagefortheindicatedpopulationis unknown. Allpregnancies have a background risk of birth defect, loss orother adverseoutcomes.In the U.S. general population, the estimated background risk of major birth defectsandmiscarriagein clinicallyrecognized pregnanciesis 2 to 4%and 15 to 20%,respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">ClinicalConsiderations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>
                           <content styleCode="italics">Fetal/NeonatalAdverse Reactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>Amphetamines, such as lisdexamfetamine dimesylate capsules, cause vasoconstriction and thereby may decrease placentalperfusion.In addition, amphetamines can stimulate uterine contractions increasing the risk ofpremature delivery.Infants born to amphetamine-dependent mothers have an increased risk ofprematuredelivery and lowbirth weight.</paragraph>
                        <paragraph>Monitorinfantsborntomothers takingamphetaminesforsymptomsofwithdrawalsuchasfeeding difficulties,irritability, agitation, andexcessivedrowsiness.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>
                           <content styleCode="italics">AnimalData</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>Lisdexamfetamine dimesylate had no apparent effects on embryo-fetal morphologicaldevelopment or survival when administered orally to pregnant rats and rabbits throughout theperiod of organogenesis at doses of up to 40 and 120 mg/kg/day, respectively.These doses areapproximately5.5and33times,respectively,themaximumrecommendedhumandose(MRHD) of70 mg/day given to adults, on amg/m<sup>2</sup>bodysurface areabasis.</paragraph>
                        <paragraph>A studywasconductedwithamphetamine (d-tol-enantiomerratioof3:1)inwhichpregnantrats received daily oral doses of 2, 6, and 10 mg/kg from gestation day 6 to lactation day 20. Alldoses caused hyperactivity and decreased weight gain in the dams.A decrease in pup survivalwas seen at all doses.A decrease in pup body weight was seen at 6 and 10 mg/kg whichcorrelated with delays in developmental landmarks, such as preputial separation and vaginalopening.Increased puplocomotoractivity wasseenat10mg/kg onday22postpartumbutnotat5 weeks postweaning.When pups were tested for reproductive performance at maturation,gestational weight gain, number of implantations, and number of delivered pups were decreasedinthe groupwhose mothers had beengiven 10 mg/kg.</paragraph>
                        <paragraph>A number of studies from the literature in rodents indicate that prenatal or early postnatalexposure to amphetamine (d- or d, l-) at doses similar to those used clinically can result in long-term neurochemical and behavioral alterations.Reported behavioral effects include learning andmemorydeficits, alteredlocomotor activity, andchanges in sexualfunction.</paragraph>
                     </text>
                     <effectiveTime value="20231117"/>
                  </section>
               </component>
               <component>
                  <section ID="LABOR_AND_DELIVERY">
                     <id root="3e081326-6aeb-dcac-2f3b-95ae20fda27b"/>
                     <code code="34079-4" displayName="LABOR &amp; DELIVERY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">RiskSummary</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>Lisdexamfetamine is a pro-drug of dextroamphetamine.Based on limited case reports inpublishedliterature,amphetamine(d-ord,l-)ispresentinhumanmilk,atrelative infantdosesof2%to13.8%ofthematernal weight-adjusteddosageandamilk/plasmaratiorangingbetween 1.9 and 7.5.There are no reports of adverse effects on the breastfed infant.Long-termneurodevelopmental effects on infants from amphetamine exposure are unknown.It is possiblethat large dosages of dextroamphetamine might interfere with milk production, especially inwomen whose lactation is not well established.Because of the potential for serious adversereactions in nursing infants, including serious cardiovascular reactions, blood pressure and heartrate increase, suppression of growth, and peripheral vasculopathy, advise patients thatbreastfeedingis notrecommended duringtreatment with lisdexamfetamine dimesylate capsules.</paragraph>
                     </text>
                     <effectiveTime value="20220130"/>
                  </section>
               </component>
               <component>
                  <section ID="PEDIATRIC_USE">
                     <id root="c2c1fec1-a868-2c9d-4ea8-7ff66504a7cd"/>
                     <code code="34081-0" displayName="PEDIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">ADHD</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>Safetyandeffectivenessoflisdexamfetamine dimesylate capsuleshavebeenestablishedinpediatricpatients withADHD ages 6 to 17 years<content styleCode="italics">[see Dosage and Administration (<linkHtml href="#_4f777e54-bf46-3e4b-45cc-e898bda0c446">2.3</linkHtml>), Adverse Reactions (<linkHtml href="#_f375ae39-09ae-27ca-d7c4-830c835a13a0">6.1</linkHtml>), ClinicalPharmacology(<linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>), and Clinical Studies (<linkHtml href="#_bab39eaf-3540-8541-210f-5c88ca1ef1bb">14.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Safety and effectiveness of lisdexamfetamine dimesylate capsules have not been established in pediatric patients below the age of6 years.</paragraph>
                        <paragraph>Safety and efficacy of lisdexamfetamine dimesylate capsules were evaluated in a double-blind, randomized, parallel-group, placebo-controlled, fixed-dose study in pediatric patients ages 4 to 5 years with ADHD, followed by a 1-year open-label extension study. In these studies, patients experienced elevated rates ofadversereactions,including weightloss,decreased BMI,decreasedappetite, insomnia,infections(upper respiratory andnasopharyngitis),irritability,and affectlability.</paragraph>
                        <paragraph>With the same lisdexamfetamine dimesylate capsules dose, mean steady state exposure of dextroamphetamine wasapproximately 44% higher in pediatric patients ages 4 to 5 years compared to the pediatric patientsages 6 to 11 years.</paragraph>
                        <paragraph>
                           <content styleCode="underline">BED</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>Safety and effectiveness of lisdexamfetamine dimesylate capsules have not been established in pediatric patients with BED less than 18 years of age.</paragraph>
                        <paragraph>
                           <content styleCode="underline">GrowthSuppression</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>Growth should be monitored during treatment with stimulants, including lisdexamfetamine dimesylate capsules, andpediatric patients who are not growing or gaining weight as expected may need to have theirtreatmentinterrupted<content styleCode="italics">[seeWarningsandPrecautions(<linkHtml href="#_d2108e06-f1e5-9e1a-86a2-59273bf634b1">5.5</linkHtml>)andAdverse Reactions(<linkHtml href="#_f375ae39-09ae-27ca-d7c4-830c835a13a0">6.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">JuvenileAnimalData</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>Studies conducted in juvenile rats and dogs at clinically relevant doses showed growthsuppression that partially or fully reversed in dogs and female rats but not in male rats after afour-weekdrug-free recovery period.</paragraph>
                        <paragraph>A study was conducted in which juvenile rats received oral doses of 4, 10, or 40 mg/kg/day oflisdexamfetamine dimesylate from day 7 to day 63 of age.These doses are approximately 0.3,0.7, and 3 times the maximum recommended human daily dose of 70 mg on a mg/m<sup>2</sup> basis for achild.Dose-related decreases in food consumption, bodyweight gain, and crown-rump lengthwere seen; after a four-week drug-free recovery period, bodyweights and crown-rump lengthshad significantly recovered in females but were still substantially reduced in males.Time tovaginal opening was delayed in females at the highest dose, but there were no drug effects onfertilitywhen the animals were mated beginningon day 85 ofage.</paragraph>
                        <paragraph>In a study in which juvenile dogs received lisdexamfetamine dimesylate for 6 months beginningat 10 weeks of age, decreased bodyweight gain was seen at all doses tested (2, 5, and 12mg/kg/day,whichare approximately0.5,1, and 3 timesthemaximum recommendedhuman dailydoseonamg/m<sup>2</sup>basisforachild).Thiseffectpartially orfullyreversed duringafour- weekdrug-free recoveryperiod.</paragraph>
                     </text>
                     <effectiveTime value="20231103"/>
                  </section>
               </component>
               <component>
                  <section ID="GERIATRIC_USE">
                     <id root="2621dc13-3223-7a79-915a-7b16922337f8"/>
                     <code code="34082-8" displayName="GERIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of lisdexamfetamine dimesylate capsules did not include sufficient numbers of subjects aged 65 and over todetermine whether they respond differently from younger subjects.Other reported clinicalexperience and pharmacokinetic data <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>)]</content> have not identified differences in responses between the elderly and younger patients.In general, dose selection foran elderly patient should start at the low end of the dosing range, reflecting the greater frequencyofdecreasedhepatic,renal,orcardiacfunction, andofconcomitantdiseaseorotherdrugtherapy.</paragraph>
                     </text>
                     <effectiveTime value="20220130"/>
                  </section>
               </component>
               <component>
                  <section ID="_9165f0d1-8ca0-b7fa-837a-310709bb0a8b">
                     <id root="8393bc1f-8773-7a2c-2470-12f37d83ce35"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Due to reduced clearance in patients with severe renal impairment (GFR 15 to &lt; 30 mL/min/1.73m<sup>2</sup>), the maximum dose should not exceed 50 mg/day.The maximum recommended dose inESRD(GFR&lt;15mL/min/1.73m<sup>2</sup>)patientsis30mg/day<content styleCode="italics">[seeClinical Pharmacology(<linkHtml href="#PHARMACOKINETICS">12.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>Lisdexamfetamineandd-amphetaminearenotdialyzable.</paragraph>
                     </text>
                     <effectiveTime value="20220130"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="DRUG_ABUSE_AND_DEPENDENCE">
               <id root="23520f3c-659d-f773-4867-fe40e71bc4a3"/>
               <code code="42227-9" displayName="DRUG ABUSE AND DEPENDENCE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20220125"/>
               <component>
                  <section ID="CONTROLLED_SUBSTANCE">
                     <id root="82b5a59f-85fa-d53e-0087-d2f19038c12f"/>
                     <code code="34085-1" displayName="CONTROLLED SUBSTANCE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph>Lisdexamfetamine dimesylate capsules contains lisdexamfetamine, a prodrug of amphetamine, a Schedule II controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20220130"/>
                  </section>
               </component>
               <component>
                  <section ID="ABUSE">
                     <id root="7109b342-c71c-f961-3d2c-9365ba44167a"/>
                     <code code="34086-9" displayName="ABUSE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph>Lisdexamfetamine dimesylate capsules has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#_1c87c681-652b-26d1-f5e9-c4bcf6a09df7">5.1</linkHtml>)].</content> Lisdexamfetamine dimesylate capsules can be diverted for non-medical use into illicit channels or distribution.</paragraph>
                        <paragraph>Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomenathat may include a strong desire to take the drug, difficulties in controlling drug use (e.g.,continuing drug use despite harmful consequences, giving a higher priority to drug use than otheractivities and obligations), and possible tolerance or physical dependence.  </paragraph>
                        <paragraph>Misuse and abuse of lisdexamfetamine, a prodrug of amphetamine, may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including lisdexamfetamine dimesylate capsules, can result in overdose and death<content styleCode="italics"> [see Overdosage (<linkHtml href="#OVERDOSAGE">10</linkHtml>)]</content>, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</paragraph>
                        <paragraph>
                           <content styleCode="underline">StudiesofLisdexamfetamine Dimesylate Capsulesin DrugAbusers</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>A randomized, double-blind, placebo-control, cross-over, abuse liability study in 38 patients withahistoryofdrugabusewasconductedwithsingle-dosesof50,100,or150mgoflisdexamfetamine dimesylate capsules,40 mg of immediate-release d-amphetamine sulphate (a controlled II substance), and 200 mg ofdiethylpropion hydrochloride (a controlled IV substance). Lisdexamfetamine dimesylate capsules 100 mg producedsignificantly less Drug Liking Effects as measured by the Drug Rating Questionnaire-Subjectscore, compared to d-amphetamine 40 mg; and 150 mg of lisdexamfetamine dimesylate capsules demonstrated similarDrug-LikingEffects comparedto40mgofd-amphetamine and200mgof diethylpropion.</paragraph>
                        <paragraph>Intravenousadministrationof50mglisdexamfetaminedimesylatetoindividualswithahistory ofdrugabuseproducedpositive subjectiveresponsesonscalesmeasuring "DrugLiking","Euphoria", "Amphetamine Effects", and "Benzedrine Effects" that were greater than placebo butlessthan thoseproducedbyan equivalent dose(20mg)ofintravenousd-amphetamine.</paragraph>
                     </text>
                     <effectiveTime value="20231117"/>
                  </section>
               </component>
               <component>
                  <section ID="DEPENDENCE">
                     <id root="42b83319-567c-27fe-28b8-29d596fab52b"/>
                     <code code="34087-7" displayName="DEPENDENCE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>9.3 Dependence</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">PhysicalDependence</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>Lisdexamfetamine dimesylate capsules may produce physical dependence.Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants including lisdexamfetamine dimesylate capsules include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.  </paragraph>
                        <paragraph>
                           <content styleCode="underline">Tolerance</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>Lisdexamfetamine dimesylate capsules may produce tolerance. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). </paragraph>
                     </text>
                     <effectiveTime value="20231103"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="OVERDOSAGE">
               <id root="33a8dfa9-71b9-c7d7-2fc7-68a5bfb8cc49"/>
               <code code="34088-5" displayName="OVERDOSAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Clinical Effects of Overdose </content>
                  </paragraph>
                  <paragraph>Overdose of CNS stimulants is characterized by the following sympathomimetic effects: </paragraph>
                  <list>
                     <item>
                        <paragraph> Cardiovascular effects including tachyarrhythmias, and hypertension or hypotension. Vasospasm, myocardial infarction, or aortic dissection may precipitate sudden cardiac death. Takotsubo cardiomyopathy may develop.</paragraph>
                     </item>
                     <item>
                        <paragraph>CNS effects including psychomotor agitation, confusion, and hallucinations. Serotonin syndrome, seizures, cerebral vascular accidents, and coma may occur.</paragraph>
                     </item>
                     <item>
                        <paragraph>Life-threatening hyperthermia (temperatures greater than 104F) and rhabdomyolysis may develop.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Overdose Management </content>
                  </paragraph>
                  <paragraph> Consider the possibility of multiple drug ingestion. The pharmacokinetic profile of lisdexamfetamine dimesylate capsulesshould be considered when treating patients with overdose. Lisdexamfetamine and d-amphetamine are not dialyzable. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.</paragraph>
               </text>
               <effectiveTime value="20231117"/>
            </section>
         </component>
         <component>
            <section ID="DESCRIPTION">
               <id root="1b729c0f-3d83-c266-9dcd-481e024981d3"/>
               <code code="34089-3" displayName="DESCRIPTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Lisdexamfetamine dimesylate, a CNS stimulant, is for once-a-day oraladministration.Thechemical designationforlisdexamfetaminedimesylateis(2<content styleCode="italics">S</content>)-2,6-Diamino-<content styleCode="italics">N</content>-[(1<content styleCode="italics">S</content>)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate.The molecular formula isC<sub>17</sub>H<sub>33</sub>N<sub>3</sub>O<sub>7</sub>S<sub>2</sub>, which corresponds to a molecular weight of 455.59.The chemicalstructureis:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM188718933344"/>
                  </paragraph>
                  <paragraph>Lisdexamfetamine dimesylate is a white to off-white powder that is freely soluble in water and practically insoluble in methylene chloride.</paragraph>
                  <paragraph>
                     <content styleCode="italics">InformationforLisdexamfetamine DimesylateCapsules:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics"/>Lisdexamfetamine dimesylate capsulescontain10mg,20 mg, 30 mg,40 mg,50 mg, 60 mg,and 70mg of lisdexamfetamine dimesylate (equivalent to 5.8 mg, 11.6 mg, 17.3 mg, 23.1 mg, 28.9 mg, 34.7mg,and 40.5 mg of lisdexamfetamine).</paragraph>
                  <paragraph>Inactiveingredients: colloidal silicon dioxide, croscarmellosesodium, magnesiumstearate,and microcrystallinecellulose. The capsule shells contain gelatin, titanium dioxide, and one or more of the following: D&amp;C Red #28 (70 mg), FD&amp;C Blue#1 (40 mg, 50 mg, 60 mg and 70 mg), FD&amp;CRed#3 (10 mg and 30 mg), FD&amp;C Red #40 (70 mg), FD&amp;CYellow#6 (30 mg and 70 mg), iron oxide black (40 mg), and iron oxide yellow (20 mg and 40 mg). The imprinting ink of the 10 mg capsules contains iron oxide black, potassium hydroxide, propylene glycol, shellac, and strong ammonia solution. The imprinting ink of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac glaze.</paragraph>
               </text>
               <effectiveTime value="20231103"/>
            </section>
         </component>
         <component>
            <section ID="CLINICAL_PHARMACOLOGY">
               <id root="aeb31c59-99dd-9d73-3599-8bb811fefd7c"/>
               <code code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20220125"/>
               <component>
                  <section ID="MECHANISM_OF_ACTION">
                     <id root="3926a243-9b8b-3e21-c61b-efe06044392e"/>
                     <code code="43679-0" displayName="MECHANISM OF ACTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Lisdexamfetamine is a prodrug of dextroamphetamine.Amphetamines are non-catecholaminesympathomimetic amines with CNS stimulant activity.The exact mode of therapeutic action inADHDand BED is not known.</paragraph>
                     </text>
                     <effectiveTime value="20220130"/>
                  </section>
               </component>
               <component>
                  <section ID="PHARMACODYNAMICS">
                     <id root="8255a656-1e8c-069f-afac-e01ff3869c3e"/>
                     <code code="43681-6" displayName="PHARMACODYNAMICS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Amphetaminesblockthereuptake ofnorepinephrineanddopamineintothepresynapticneuronand increase the release of these monoamines into the extraneuronal space.The parent drug,lisdexamfetamine, does not bind to the sites responsible for the reuptake of norepinephrine anddopamine<content styleCode="italics">invitro</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220130"/>
                  </section>
               </component>
               <component>
                  <section ID="PHARMACOKINETICS">
                     <id root="6dd6a2d9-8c3d-7835-7ea0-63c4acb1b506"/>
                     <code code="43682-4" displayName="PHARMACOKINETICS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Pharmacokinetic studies after oral administration of lisdexamfetamine dimesylate have beenconducted in healthy adult (capsule and chewable tablet formulations) and pediatric (6 to 12years) patients with ADHD (capsule formulation). After single dose administration oflisdexamfetamine dimesylate, pharmacokinetics of dextroamphetamine was found to be linearbetween 30mg and70mgin apediatric study(6 to12 years),and between50 mgand 250mginan adult study. Dextroamphetamine pharmacokinetic parameters following administration oflisdexamfetamine dimesylate in adults exhibited low inter-subject (&lt;25%) and intra-subject(&lt;8%) variability. There is no accumulation of lisdexamfetamine and dextroamphetamine atsteady statein healthy adults.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>
                           <content styleCode="italics">Capsuleformulation</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>Following single-dose oral administration of lisdexamfetamine dimesylate capsule (30 mg, 50 mg, or 70 mg) inpatients ages 6 to 12 years with ADHD under fasted conditions, T<sub>max</sub>of lisdexamfetamine anddextroamphetamine was reached at approximately 1 hour and 3.5 hours post dose, respectively.Weight/Dose normalized AUC and C<sub>max</sub>values were the same in pediatric patients ages 6 to 12yearsastheadults followingsingledoses of 30mgto 70 mglisdexamfetamine dimesylatecapsule.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effectoffoodoncapsuleformulation</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>Neither food (a high fat meal or yogurt) nor orange juice affects the observed AUC and C<sub>max</sub> ofdextroamphetamineinhealthyadults aftersingle-doseoraladministrationof70mgoflisdexamfetamine dimesylate capsules. Food prolongs T<sub>max</sub> by approximately 1 hour (from 3.8 hours at fasted state to 4.7 hours afterahighfatmealorto4.2hourswithyogurt).Afteran8-hourfast,theAUCfordextroamphetaminefollowingoraladministrationoflisdexamfetaminedimesylateinsolutionand as intact capsules wereequivalent.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>Plasma concentrations of unconverted lisdexamfetamine are low and transient, generallybecoming non-quantifiable by 8 hours after administration.The plasma elimination half-life oflisdexamfetaminetypically averagedlessthanonehourinvolunteersages6years andolder.Theplasma elimination half-life of dextroamphetamine was approximately 8.6 to 9.5 hours inpediatricpatients 6to 12years and 10 to 11.3 hours in healthyadults.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>Lisdexamfetamine is converted to dextroamphetamine and l-lysine primarily in blood due to thehydrolytic activity of red blood cells after oral administration of lisdexamfetamine dimesylate.<content styleCode="italics">In vitro</content> data demonstrated that red blood cells have a high capacity for metabolism oflisdexamfetamine; substantial hydrolysis occurred even at low hematocrit levels (33% ofnormal). Lisdexamfetamineis notmetabolizedby cytochrome P450enzymes.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>Following oral administration of a 70 mg dose of radiolabeled lisdexamfetamine dimesylate to 6healthy subjects,approximately96%oftheoraldoseradioactivitywasrecoveredintheurineand only 0.3% recovered in the feces over a period of 120 hours.Of the radioactivity recoveredin the urine, 42% of the dose was related to amphetamine, 25% to hippuric acid, and 2% to intactlisdexamfetamine.</paragraph>
                        <paragraph>
                           <content styleCode="underline">SpecificPopulations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>ExposuresofdextroamphetamineinspecificpopulationsaresummarizedinFigure1.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure1:SpecificPopulations*:</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM891508802937"/>
                        </paragraph>
                        <paragraph>*Figure 1 shows the geometric mean ratios and the 90% confidence limits for C<sub>max</sub> and AUC of d-amphetamine.Comparisonforgenderusesmalesasthereference.Comparisonforageuses55 to 64yearsasthereference.</paragraph>
                        <paragraph>
                           <content styleCode="italics">DrugInteractionStudies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>EffectsofotherdrugsontheexposuresofdextroamphetaminearesummarizedinFigure2.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure2:EffectofOtherDrugsonLisdexamfetamine Dimesylate Capsules:</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"/>
                           <renderMultiMedia referencedObject="MM828767931450"/>
                        </paragraph>
                        <paragraph>Theeffects oflisdexamfetamine dimesylate capsulesontheexposuresofotherdrugs aresummarizedinFigure3.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">Figure3:EffectofLisdexamfetamine Dimesylate CapsulesonOtherDrugs:</content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM548774666486"/>
                        </paragraph>
                        <paragraph/>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20231117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="NONCLINICAL_TOXICOLOGY">
               <id root="18f3dd5c-1310-6ea5-37b3-382369c00a34"/>
               <code code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20220125"/>
               <component>
                  <section ID="CARCINOGENESIS_AND_MUTAGENESIS_AND_IMPAIRMENT_OF_FERTILITY">
                     <id root="a4b9b4be-7699-89cc-4aba-e96dcf2c6ff0"/>
                     <code code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>Carcinogenicity studies of lisdexamfetamine dimesylate have not been performed.No evidenceof carcinogenicity was found in studies in which d-, l-amphetamine (enantiomer ratio of 1:1) wasadministered to mice and rats in the diet for 2 years at doses of up to 30 mg/kg/day in male mice,19mg/kg/day in femalemice,and5mg/kg/day in maleandfemale rats.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>Lisdexamfetamine dimesylate was not clastogenic in the mouse bone marrow micronucleus test<content styleCode="italics">in vivo</content> and was negative when tested in the <content styleCode="italics">E. coli</content> and <content styleCode="italics">S. typhimurium</content> components of the Amestestand in the L5178Y/TK<sup>+/-</sup>mouse lymphomaassay <content styleCode="italics">in vitro</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">ImpairmentofFertility</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>Amphetamine(d-tol-enantiomerratioof3:1)didnotadverselyaffect fertilityorearly embryonicdevelopmentin the rat atdoses of up to 20 mg/kg/day.</paragraph>
                     </text>
                     <effectiveTime value="20231106"/>
                  </section>
               </component>
               <component>
                  <section ID="ANIMAL_PHARMACOLOGY_AND_OR_TOXICOLOGY_SECTION">
                     <id root="edbd3a0d-0af8-500d-78d3-5dbcbd85ecb9"/>
                     <code code="34091-9" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>Acute administration of high doses of amphetamine (d- or d, l-) has been shown to produce long-lasting neurotoxic effects, including irreversible nerve fiber damage, in rodents. The significanceofthese findings to humans is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20231106"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="CLINICAL_STUDIES">
               <id root="e651e9b3-99af-8030-ad75-811d9196f5ef"/>
               <code code="34092-7" displayName="CLINICAL STUDIES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20220125"/>
               <component>
                  <section ID="_bab39eaf-3540-8541-210f-5c88ca1ef1bb">
                     <id root="e391006f-8fea-4258-7d37-589c835a4581"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>14.1	Attention Deficit Hyperactivity Disorder (ADHD)</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">PediatricPatients Ages6to12YearswithADHD</content>
                        </paragraph>
                        <paragraph>Adouble-blind,randomized,placebo-controlled,parallel-groupstudy(Study1)wasconducted in pediatric patients ages 6 to 12 years (N=290) who met DSM-IV criteria for ADHD (either thecombined type or the hyperactive-impulsive type).Patients were randomized to receive finaldoses of 30 mg, 50 mg, or 70 mg of lisdexamfetamine dimesylate capsules or placebo once daily in the morning for a totalof four weeks of treatment.All patients receiving lisdexamfetamine dimesylate capsules were initiated on 30 mg for thefirst week of treatment.Patients assigned to the 50 mg and 70 mg dose groups were titrated by20 mg per week until they achieved their assigned dose.The primary efficacy outcome waschange in Total Score from baseline to endpoint in investigator ratings on the ADHD RatingScale (ADHD-RS), an 18-item questionnaire with a score range of 0 to 54 points that measures thecore symptoms of ADHD which includes both hyperactive/impulsive and inattentive subscales.Endpoint was defined as the last post-randomization treatment week (i.e., Weeks 1 through 4) for which a valid score was obtained.All lisdexamfetamine dimesylate capsule dose groups were superior to placebo in theprimary efficacy outcome.Mean effects at all doses were similar; however, the highest dose (70mg/day) was numerically superior to both lower doses (Study 1 in Table 6).The effects weremaintained throughout the day based on parent ratings (Conners Parent Rating Scale) in themorning (approximately 10 am), afternoon (approximately 2 pm), and early evening(approximately6 pm).</paragraph>
                        <paragraph>A double-blind, placebo-controlled, randomized, crossover design, analog classroom study(Study 2) was conducted in pediatric patients ages 6 to 12 years (N=52) who met DSM-IVcriteria for ADHD (either the combined type or the hyperactive-impulsive type).Following a 3-week open-label dose optimization with Adderall XR<sup></sup>, patients were randomly assigned tocontinue their optimized dose of Adderall XR (10 mg, 20 mg, or 30 mg), lisdexamfetamine dimesylate capsules (30 mg, 50mg, or 70 mg), or placebo once daily in the morning for 1 week each treatment.Efficacyassessments were conducted at 1, 2, 3, 4.5, 6, 8, 10, and 12 hours post-dose using the Swanson,Kotkin, Agler, M.Flynn, and Pelham Deportment scores (SKAMP-DS), a 4-item subscale of theSKAMP with scores ranging from 0 to 24 points that measures deportment problems leading toclassroom disruptions.A significant difference in patient behavior, based upon the average ofinvestigator ratings on the SKAMP-DS across the 8 assessments were observed between patientswhen they received lisdexamfetamine dimesylate capsules compared to patients when they received placebo (Study 2 inTable 6). The drug effect reached statistical significance from hours 2 to 12 post-dose, but wasnotsignificant at 1 hour.</paragraph>
                        <paragraph>A second double-blind, placebo-controlled, randomized, crossover design, analog classroomstudy (Study 3) was conducted in pediatric patients ages 6 to 12 years (N=129) who met DSMIV criteria for ADHD (either the combined type or the hyperactive-impulsive type).Following a4-week open-label dose optimization with lisdexamfetamine dimesylate capsules (30 mg, 50 mg, 70 mg), patients wererandomly assigned to continue their optimized dose of lisdexamfetamine dimesylate capsules or placebo once daily in themorning for 1 week each treatment.A significant difference in patient behavior, based upon theaverage of investigator ratings on the SKAMP-Deportment scores across all 7 assessmentsconducted at1.5, 2.5,5, 7.5, 10, 12,and 13 hourspost-dose, wereobserved between patients when they received lisdexamfetamine dimesylate capsules compared to patients when they received placebo(Study3 inTable 6, Figure 4).</paragraph>
                        <paragraph>
                           <content styleCode="underline">PediatricPatients Ages13to17YearswithADHD</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>A double-blind, randomized, placebo-controlled, parallel-group study (Study 4) was conductedin pediatric patients ages 13 to 17 years (N=314) who met DSM-IV criteria for ADHD.In this study, patients were randomized in a 1:1:1:1 ratio to a daily morning dose of lisdexamfetamine dimesylate capsules (30mg/day, 50 mg/day or 70 mg/day) or placebo for a total of four weeks of treatment.All patients receiving lisdexamfetamine dimesylate capsules were initiated on 30 mg for the first week of treatment.Patients assignedto the 50 mg and 70 mg dose groups were titrated by 20 mg per week until they achieved theirassigned dose.The primary efficacy outcome was change in Total Score from baseline toendpoint in investigator ratings on the ADHD Rating Scale (ADHD-RS).Endpoint was definedas the last post-randomization treatment week (i.e., Weeks 1 through 4) for which a valid scorewas obtained.All lisdexamfetamine dimesylate capsules dose groups were superior to placebo in the primary efficacyoutcome (Study 4 in Table 6).</paragraph>
                        <paragraph>
                           <content styleCode="underline">PediatricPatients Ages6to17Years:Short-TermTreatment inADHD</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>A double-blind, randomized, placebo- and active-controlled parallel-group, dose-optimizationstudy (Study 5) was conducted in pediatric patients ages 6 to 17 years (n=336) who met DSM-IVcriteria for ADHD.In this eight-week study, patients were randomized to a daily morning doseof lisdexamfetamine dimesylate capsules (30, 50 or 70 mg/day), an active control, or placebo (1:1:1).The study consistedof a Screening and Washout Period (up to 42 days), a 7-week Double-blind Evaluation Period(consisting of a 4-week Dose-Optimization Period followed by a 3-week Dose-MaintenancePeriod), and a 1-week Washout and Follow-up Period.During the Dose Optimization Period,subjects were titrated until an optimal dose, based on tolerability and investigators judgment,was reached.lisdexamfetamine dimesylate capsules showed significantly greater efficacy than placebo.The placebo-adjusted mean reduction from baseline in the ADHD-RS-IV total score was 18.6.Subjects onlisdexamfetamine dimesylate capsules also showed greater improvement on the Clinical Global Impression-Improvement(CGI-I) rating scalecomparedto subjects on placebo(Study 5 in Table6).</paragraph>
                        <paragraph>
                           <content styleCode="underline">PediatricPatients Ages6to17Years: MaintenanceTreatmentinADHD</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>Maintenance of Efficacy Study (Study 6) - A double-blind, placebo-controlled, randomizedwithdrawal study was conducted in pediatric patients ages 6 to 17 years (N=276) who met thediagnosis of ADHD (DSM-IV criteria).A total of 276 patients were enrolled into the study, 236patients participated in Study 5 and 40 subjects directly enrolled. Subjects were treated withopen-labellisdexamfetamine dimesylate capsulesforatleast26weekspriortobeingassessedforentryintotherandomized withdrawal period.Eligible patients had to demonstrate treatment response asdefined by CGI-S &lt;3 and Total Score on the ADHD-RS 22.Patients that maintained treatmentresponse for 2 weeks at the end of the open label treatment period were eligible to be randomizedto ongoing treatment with the same dose of lisdexamfetamine dimesylate capsules (N=78) or switched to placebo (N=79)duringthedouble-blindphase.Patientswereobservedforrelapse(treatmentfailure)duringthe6 week double blind phase.A significantly lower proportion of treatment failures occurredamonglisdexamfetamine dimesylate capsulessubjects(15.8%)comparedtoplacebo(67.5%)atendpoint oftherandomized withdrawal period. The endpoint measurement was defined as the last post-randomization treatment week atwhich a valid ADHD-RS Total Scoreand CGI-S wereobserved.Treatmentfailurewasdefined asa50%increase(worsening)intheADHD-RS Total Score and a 2-point increase in the CGI-S score compared to scores at entry into the double-blindrandomizedwithdrawalphase.Subjects whowithdrewfromtherandomizedwithdrawal period and who did not provide efficacy data at their last on-treatment visit were classified astreatmentfailures (Study6, Figure 5).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults:Short-TermTreatmentinADHD</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>Adouble-blind,randomized,placebo-controlled, parallel-groupstudy(Study7)wasconductedin adults ages 18 to 55 (N=420) who met DSM-IV criteria for ADHD.In this study, patientswere randomized to receive final doses of 30 mg, 50 mg, or 70 mg of lisdexamfetamine dimesylate capsules or placebo fora total of four weeks of treatment.All patients receiving lisdexamfetamine dimesylate capsules were initiated on 30 mg forthe first week of treatment.Patients assigned to the 50 mg and 70 mg dose groups were titratedby 20 mg per week until they achieved their assigned dose.The primary efficacy outcome waschange in Total Score from baseline to endpoint in investigator ratings on the ADHD RatingScale (ADHD-RS).Endpoint was defined as the last post-randomization treatment week (i.e.,Weeks 1 through 4) for which a valid score was obtained.All lisdexamfetamine dimesylate capsules dose groups weresuperiorto placebointheprimary efficacy outcome(Study 7 in Table6).</paragraph>
                        <paragraph>The second study was a multi-center, randomized, double-blind, placebo-controlled, cross-over,modified analog classroom study (Study 8) of lisdexamfetamine dimesylate capsules to simulate a workplace environmentin 142 adults ages 18 to 55 who met DSM-IV-TR criteria for ADHD.There was a 4-week open-label, dose optimization phase with lisdexamfetamine dimesylate capsules (30 mg/day, 50 mg/day, or 70 mg/day in themorning). Patients were then randomized to one of two treatment sequences: 1) lisdexamfetamine dimesylate capsules (optimized dose) followed by placebo, each for one week, or 2) placebo followed bylisdexamfetamine dimesylate capsules, each for one week.Efficacy assessments occurred at the end of each week, usingthe Permanent Product Measure of Performance (PERMP), a skill-adjusted math test thatmeasures attention in ADHD.PERMP total score results from the sum of the number of mathproblems attempted plus the number of math problems answered correctly.lisdexamfetamine dimesylate capsulestreatment, compared to placebo, resulted in a statistically significant improvement in attentionacross all post-dose time points, as measured by average PERMP total scores over the course ofone assessment day, as well as at each time point measured.The PERMP assessments wereadministeredat pre-dose(-0.5 hours)and at2, 4, 8, 10, 12,and 14hours post-dose(Study 8in Table 6,Figure6).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults:MaintenanceTreatmentinADHD</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"/>A double-blind, placebo-controlled, randomized withdrawal design study (Study 9) wasconducted in adults ages 18 to 55 (N=123) who had a documented diagnosis of ADHD or metDSM-IVcriteriaforADHD.Atstudyentry, patientsmusthavehaddocumentationoftreatmentwith lisdexamfetamine dimesylate capsules for a minimum of 6 months and had to demonstrate treatment response asdefined byClinicalGlobal ImpressionSeverity(CGI-S) 3andTotalScoreontheADHD-RS &lt;22.ADHD-RS Total Score is a measure of core symptoms of ADHD.The CGI-S scoreassesses the clinicians impression of the patients current illness state and ranges from 1 (not atall ill) to 7 (extremely ill).Patients that maintained treatment response at Week 3 of the openlabel treatmentphase (N=116)were eligible toberandomizedtoongoingtreatmentwiththesame dose of lisdexamfetamine dimesylate capsules (N=56) or switched to placebo (N=60) during the double-blind phase.Patients were observed for relapse (treatment failure) during the 6-week double-blind phase.Theefficacyendpoint wastheproportionofpatientswithtreatmentfailure duringthedouble-blind phase.Treatment failure was defined as a 50% increase (worsening) in the ADHD-RS TotalScore and 2-point increase in the CGI-S score compared to scores at entry into the double-blindphase.Maintenance of efficacy for patients treated with lisdexamfetamine dimesylate capsules was demonstrated by thesignificantly lower proportion of patients with treatment failure (9%) compared to patientsreceivingplacebo(75%) atendpointduring thedouble-blindphase (Study9,Figure 7).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 6:SummaryofPrimaryEfficacy ResultsfromShort-termStudiesoflisdexamfetamine dimesylate capsulesinPediatricPatients (Ages 6to 17) andAdults withADHD</content>
                        </paragraph>
                        <table rules="all">
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Study</content>
                                    <content styleCode="bold">Number</content>
                                    <content styleCode="bold">(Age</content>
                                    <content styleCode="bold">range)</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Primary</content>
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">TreatmentGroup</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">MeanBaseline<br/>Score</content>
                                    <content styleCode="bold">(SD)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">LSMeanChange</content>
                                    <content styleCode="bold">fromBaseline(SE)</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="bold">Placebo-subtracted</content>
                                    <content styleCode="bold">Difference<sup>a</sup><br/>(95%CI)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2"> Study1 (6-12 years) </td>
                                 <td> ADHD-RSIV </td>
                                 <td> lisdexamfetamine dimesylate capsules(30mg/day)* </td>
                                 <td> 43.2(6.7) </td>
                                 <td> -21.8(1.6) </td>
                                 <td> -15.6(-19.9,-11.2) </td>
                              </tr>
                              <tr>
                                 <td>  </td>
                                 <td> lisdexamfetamine dimesylate capsules(50mg/day)* </td>
                                 <td> 43.3(6.7) </td>
                                 <td> -23.4(1.6) </td>
                                 <td> -17.2(-21.5,-12.9) </td>
                              </tr>
                              <tr>
                                 <td>  </td>
                                 <td>  </td>
                                 <td> lisdexamfetamine dimesylate capsules(70mg/day)* </td>
                                 <td> 45.1(6.8) </td>
                                 <td> -26.7(1.5) </td>
                                 <td> -20.5(-24.8,-16.2) </td>
                              </tr>
                              <tr>
                                 <td>  </td>
                                 <td>  </td>
                                 <td> Placebo </td>
                                 <td> 42.4(7.1) </td>
                                 <td> -6.2(1.6) </td>
                                 <td> - </td>
                              </tr>
                              <tr>
                                 <td> Study2 (6-12 years) </td>
                                 <td> AverageSKAMP-DS </td>
                                 <td>
                                    <content styleCode="bold"></content> lisdexamfetamine dimesylate capsules(30, 50or70mg/day)* </td>
                                 <td>
                                    <content styleCode="bold"></content> --<sup>b</sup>
                                 </td>
                                 <td>
                                    <content styleCode="bold"></content> 0.8(0.1)<sup>d</sup>
                                 </td>
                                 <td>
                                    <content styleCode="bold"></content> -0.9(-1.1,-0.7) </td>
                              </tr>
                              <tr>
                                 <td>  </td>
                                 <td>  </td>
                                 <td> Placebo </td>
                                 <td> --<sup>b</sup>
                                 </td>
                                 <td> 1.7(0.1)<sup>d</sup>
                                 </td>
                                 <td> - </td>
                              </tr>
                              <tr>
                                 <td rowspan="2"> Study3 (6-12 years) </td>
                                 <td> AverageSKAMP-DS </td>
                                 <td> lisdexamfetamine dimesylate capsules(30,50or70mg/day)* </td>
                                 <td> 0.9(1.0)<sup>c</sup>
                                 </td>
                                 <td> 0.7(0.1)<sup>d</sup>
                                 </td>
                                 <td> -0.7(-0.9,-0.6) </td>
                              </tr>
                              <tr>
                                 <td>  </td>
                                 <td> Placebo </td>
                                 <td> 0.7(0.9)<sup>c</sup>
                                 </td>
                                 <td> 1.4(0.1)<sup>d</sup>
                                 </td>
                                 <td> - </td>
                              </tr>
                              <tr>
                                 <td rowspan="2"> Study4 (13-17 years) </td>
                                 <td> ADHD-RSIV </td>
                                 <td> lisdexamfetamine dimesylate capsules(30mg/day)* </td>
                                 <td> 38.3(6.7) </td>
                                 <td> -18.3(1.2) </td>
                                 <td> -5.5(-9.0,-2.0) </td>
                              </tr>
                              <tr>
                                 <td>  </td>
                                 <td> lisdexamfetamine dimesylate capsules(50mg/day)* </td>
                                 <td> 37.3(6.3) </td>
                                 <td> -21.1(1.3) </td>
                                 <td> -8.3(-11.8,-4.8) </td>
                              </tr>
                              <tr>
                                 <td>  </td>
                                 <td>  </td>
                                 <td> lisdexamfetamine dimesylate capsules(70mg/day)* </td>
                                 <td> 37.0(7.3) </td>
                                 <td> -20.7(1.3) </td>
                                 <td> -7.9(-11.4,-4.5) </td>
                              </tr>
                              <tr>
                                 <td>  </td>
                                 <td>  </td>
                                 <td> Placebo </td>
                                 <td> 38.5(7.1) </td>
                                 <td> -12.8(1.2) </td>
                                 <td> - </td>
                              </tr>
                              <tr>
                                 <td rowspan="2"> Study5 (6-17 years) </td>
                                 <td> ADHD-RSIV </td>
                                 <td> lisdexamfetamine dimesylate capsules(30, 50or70mg/day)* </td>
                                 <td> 40.7(7.3) </td>
                                 <td> -24.3(1.2) </td>
                                 <td> -18.6(-21.5,-15.7) </td>
                              </tr>
                              <tr>
                                 <td>  </td>
                                 <td> Placebo </td>
                                 <td> 41.0(7.1) </td>
                                 <td> -5.7(1.1) </td>
                                 <td> - </td>
                              </tr>
                              <tr>
                                 <td rowspan="2"> Study7 (18-55 years) </td>
                                 <td> ADHD-RSIV </td>
                                 <td> lisdexamfetamine dimesylate capsules(30mg/day)* </td>
                                 <td> 40.5(6.2) </td>
                                 <td> -16.2(1.1) </td>
                                 <td> -8.0(-11.5,-4.6) </td>
                              </tr>
                              <tr>
                                 <td>  </td>
                                 <td> lisdexamfetamine dimesylate capsules(50mg/day)* </td>
                                 <td> 40.8(7.3) </td>
                                 <td> -17.4(1.0) </td>
                                 <td> -9.2(-12.6,-5.7) </td>
                              </tr>
                              <tr>
                                 <td>  </td>
                                 <td>  </td>
                                 <td> lisdexamfetamine dimesylate capsules(70mg/day)* </td>
                                 <td> 41.0(6.0) </td>
                                 <td> -18.6(1.0) </td>
                                 <td> -10.4(-13.9,-6.9) </td>
                              </tr>
                              <tr>
                                 <td>  </td>
                                 <td>  </td>
                                 <td> Placebo </td>
                                 <td> 39.4(6.4) </td>
                                 <td> -8.2(1.4) </td>
                                 <td> - </td>
                              </tr>
                              <tr>
                                 <td rowspan="2"> Study8 (18-55 years) </td>
                                 <td> AveragePERMP </td>
                                 <td> lisdexamfetamine dimesylate capsules(30, 50or70mg/day)* </td>
                                 <td> 260.1(86.2)<sup>c</sup>
                                 </td>
                                 <td> 312.9(8.6)<sup>d</sup>
                                 </td>
                                 <td> 23.4(15.6,31.2) </td>
                              </tr>
                              <tr>
                                 <td>  </td>
                                 <td> Placebo </td>
                                 <td> 261.4(75.0)<sup>c</sup>
                                 </td>
                                 <td> 289.5(8.6)<sup>d</sup>
                                 </td>
                                 <td> - </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold"/>SD:standard deviation;SE:standard error;LSMean:least-squaresmean;CI:confidenceinterval. <sup>a</sup>Difference(drugminusplacebo) inleast-squaresmeanchangefrombaseline. <sup/>
                        </paragraph>
                        <paragraph>
                           <sup>b</sup>Pre-doseSKAMP-DS wasnotcollected. </paragraph>
                        <paragraph>
                           <sup>c</sup> Pre-dose SKAMP-DS (Study3)or PERMP (Study 8) totalscore,averaged over both periods. <sup/>
                        </paragraph>
                        <paragraph>
                           <sup>d</sup> LS Mean for SKAMP-DS (Study 2 and 3) or PERMP (Study 8) is post-dose average score over all sessions of the treatment day, rather thanchangefrombaseline. </paragraph>
                        <paragraph> *Dosesstatisticallysignificantlysuperiortoplacebo.</paragraph>
                        <paragraph>
                           <content styleCode="bold"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 4 LS Mean SKAMP Deportment Subscale Score by Treatment and Time-point for Pediatric Patients Ages 6 to 12 with ADHD after 1 Week ofDoubleBlind Treatment (Study 3</content>)</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM862504623320"/>
                        </paragraph>
                        <paragraph>Higher score on the SKAMP-Deportment scale indicates more severe symptoms </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 5Kaplan-Meier Estimated Proportion of Patients with Treatment Failure forPediatricPatients Ages 6 to 17 (Study6)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="MM669656274193"/>
                           </content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">Figure6 LS Mean (SE) PERMP Total Score by Treatment and Time-point forAdultsAges18to55withADHDafter 1WeekofDoubleBlind Treatment(Study8)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"/>
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="MM598493153659"/>
                           </content>
                        </paragraph>
                        <paragraph>Higher score on the PERMP scale indicates less severe symptoms. </paragraph>
                        <paragraph>
                           <content styleCode="bold"/>
                           <content styleCode="bold">Figure7 Kaplan-Meier Estimated Proportion of Subjects with Relapse in Adults withADHD(Study 9)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"/>
                           <renderMultiMedia referencedObject="MM598341453060"/>
                        </paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20231117"/>
                  </section>
               </component>
               <component>
                  <section ID="_ce13a1ec-8b23-c88d-70c0-b8a8197151dd">
                     <id root="aab05ac1-31ca-ade2-f09a-b517da306ea7"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>14.2	Binge Eating Disorder (BED)</title>
                     <text>
                        <paragraph>Aphase2study evaluatedtheefficacy oflisdexamfetamine dimesylate capsules30,50and70mg/daycompared toplacebo in reducing the number of binge days/week in adults with at least moderate to severe BED.Thisrandomized, double-blind, parallel-group, placebo-controlled, forced-dose titration study (Study10) consisted of an 11-week double-blind treatment period (3 weeks of forced-dose titrationfollowed by 8 weeks of dose maintenance). Lisdexamfetamine dimesylate capsules 30 mg/day was not statistically differentfrom placebo on the primary endpoint. The 50 and 70 mg/day doses were statistically superior toplaceboonthe primary endpoint.</paragraph>
                        <paragraph>Theefficacy oflisdexamfetamine dimesylate capsulesinthetreatmentofBEDwasdemonstratedintwo12-week randomized,double-blind,multi-center,parallel-group,placebo-controlled,dose-optimizationstudies (Study 11 and Study 12) in adults aged 18 to 55 years (Study 11: N=374, Study 12: N=350)withmoderate tosevereBED.Adiagnosis ofBEDwasconfirmedusingDSM-IVcriteria forBED.Severity ofBEDwasdeterminedbasedonhaving atleast3bingedaysperweekfor2weeksprior to the baseline visit and on having a Clinical Global Impression Severity (CGI-S) score of 4 atthebaseline visit.Forbothstudies,abingedaywasdefined asadaywithatleast1bingeepisode, asdetermined fromthe subjects daily binge diary.</paragraph>
                        <paragraph>Both12-week studiesconsistedofa4-weekdose-optimizationperiodandan8-weekdose-maintenanceperiod.Duringdose-optimization,subjectsassignedto lisdexamfetamine dimesylate capsulesbegan treatment at the titration dose of 30 mg/day and, after 1 week of treatment, were subsequentlytitrated to 50 mg/day.Additional increases to 70 mg/day were made as tolerated and clinicallyindicated.Following thedose-optimizationperiod, subjectscontinuedontheiroptimized doseforthedurationof the dose-maintenanceperiod.</paragraph>
                        <paragraph>Theprimary efficacyoutcomeforthetwostudieswasdefinedasthechange frombaselineatWeek12inthenumberofbingedaysperweek.Baselineisdefinedastheweekly averageofthenumberof binge days per week for the 14 days prior to the baseline visit.Subjects from both studies onlisdexamfetamine dimesylate capsules had a statistically significantly greater reduction from baseline in mean number ofbingedaysperweekatWeek12.Inaddition,subjects onlisdexamfetamine dimesylate capsulesshowedgreater improvement as compared to placebo across key secondary outcomes with higher proportion ofsubjectsratedimprovedontheCGI-Iratingscale, higherproportionofsubjectswith4-weekbingecessation, and greater reduction in the Yale-Brown Obsessive Compulsive Scale Modified forBingeEating (Y-BOCS-BE) totalscore.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table7:SummaryofPrimaryEfficacy ResultsinBED</content>
                        </paragraph>
                        <table frame="box" rules="all">
                           <tbody align="center">
                              <tr>
                                 <td>
                                    <content styleCode="bold">StudyNumber</content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">TreatmentGroup</content>
                                 </td>
                                 <td colspan="3">
                                    <content styleCode="bold">PrimaryEfficacyMeasure:BingeDays perWeekatWeek12</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>  </td>
                                 <td>
                                    <content styleCode="bold"></content>
                                 </td>
                                 <td colspan="2">
                                    <content styleCode="bold">MeanBaselineScore(SD)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">LS Mean Change </content>
                                    <content styleCode="bold">fromBaseline(SE)</content>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Placebo-subtractedDifference<sup>a</sup>
                                    </content>
                                    <content styleCode="bold">(95%CI)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td> Study11 </td>
                                 <td colspan="2"> Lisdexamfetamine Dimesylate Capsules(50or70mg/day)* </td>
                                 <td> 4.79(1.27) </td>
                                 <td> -3.87(0.12) </td>
                                 <td> -1.35(-1.70,-1.01) </td>
                              </tr>
                              <tr>
                                 <td>  </td>
                                 <td colspan="2"> Placebo </td>
                                 <td> 4.60(1.21) </td>
                                 <td> -2.51(0.13) </td>
                                 <td> - </td>
                              </tr>
                              <tr>
                                 <td> Study12 </td>
                                 <td colspan="2"> Lisdexamfetamine Dimesylate Capsules(50or70mg/day)* </td>
                                 <td> 4.66(1.27) </td>
                                 <td> -3.92(0.14) </td>
                                 <td> -1.66(-2.04,-1.28) </td>
                              </tr>
                              <tr>
                                 <td>  </td>
                                 <td colspan="2"> Placebo </td>
                                 <td> 4.82(1.42) </td>
                                 <td> -2.26(0.14) </td>
                                 <td> - </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold"/>SD:standard deviation;SE:standard error;LSMean:least-squaresmean;CI:confidenceinterval. <sup/>
                        </paragraph>
                        <paragraph>
                           <sup>a</sup>Difference(drugminus placebo)inleast-squares meanchangefrombaseline. </paragraph>
                        <paragraph>*Dosesstatisticallysignificantlysuperiortoplacebo.</paragraph>
                        <paragraph>Adouble-blind,placebocontrolled,randomizedwithdrawaldesignstudy(Study13)wasconducted to evaluate maintenance of efficacy based on time to relapse between lisdexamfetamine dimesylate capsules andplacebo in adults aged 18 to 55 (N=267) with moderate to severe BED.In this longer-term studypatients who had responded to lisdexamfetamine dimesylate capsules in the preceding 12-week open-label treatment phasewere randomized to continuation of lisdexamfetamine dimesylate capsules or placebo for up to 26 weeks of observation forrelapse.Response in the open-label phase was defined as 1 or fewer binge days each week for fourconsecutiveweekspriortothelastvisitattheendofthe12-weekopen-labelphaseandaCGI-Sscoreof2orlessatthesamevisit.Relapse duringthedouble-blindphasewasdefined ashaving2ormorebingedayseachweekfortwoconsecutiveweeks(14days) priortoanyvisitandhavingan increase in CGI-S score of 2 or more points compared to the randomized-withdrawal baseline.Maintenance of efficacy for patients who had an initial response during the open-label period andthen continued on lisdexamfetamine dimesylate capsules during the 26-week double-blind randomized-withdrawal phasewasdemonstratedwithlisdexamfetamine dimesylate capsules beingsuperioroverplaceboasmeasuredbytimetorelapse. </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">Figure8 Kaplan-MeierEstimatedProportionsofSubjectswithRelapseinAdultswith BED(Study 13)</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM697031100865"/>
                        </paragraph>
                        <paragraph>Examinationofpopulationsubgroups basedonage(therewerenopatients over65),gender, andracedidnotreveal anyclearevidence ofdifferentialresponsivenessinthetreatment ofBED.</paragraph>
                        <paragraph/>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20231117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="HOW_SUPPLIED">
               <id root="d6fd45e0-dc38-3134-d301-cc53ad58133e"/>
               <code code="34069-5" displayName="HOW SUPPLIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20231103"/>
               <component>
                  <section ID="_9d981a0f-1d00-5650-1db5-ccb46ffefe8b">
                     <id root="9f517601-edb0-0f1e-cfd0-7764b0df6832"/>
                     <code code="34069-5" displayName="HOW SUPPLIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>LisdexamfetamineDimesylateCapsules are supplied as follows:</paragraph>
                        <paragraph>Capsules 10 mg: Hard gelatin capsule with EEC pink opaque body and EEC pink opaque cap. Imprinted APO L10 in black ink. White to off-white granular fill.</paragraph>
                        <paragraph>Bottlesof 100, NDC60505-4739-01   </paragraph>
                        <paragraph> Capsules 20 mg: Hard gelatin capsule with ivory opaque body and ivory opaque cap. Imprinted APO L20 in black ink. White to off-white granular fill.</paragraph>
                        <paragraph> Bottlesof 100, NDC60505-4740-01    </paragraph>
                        <paragraph>Capsules 30 mg: Hard gelatin capsule with white opaque body and orange opaque cap. Imprinted APO L30 in black ink. White to off-white granular fill.    </paragraph>
                        <paragraph>Bottlesof 100, NDC60505-4741-01    </paragraph>
                        <paragraph>Capsules 40 mg: Hard gelatin capsule with white opaque body and dark green opaque cap. Imprinted APO L40 in black ink. White to off-white granular fill.   </paragraph>
                        <paragraph> Bottlesof 100, NDC60505-4742-01    </paragraph>
                        <paragraph>Capsules 50 mg: Hard gelatin capsule with white opaque body and light blue opaque cap. Imprinted APO L50 in black ink. White to off-white granular fill.   </paragraph>
                        <paragraph> Bottlesof 100, NDC60505-4743-01    </paragraph>
                        <paragraph>Capsules 60 mg: Hard gelatin capsule with aqua blue opaque body and aqua blue opaque cap. Imprinted APO L60 in black ink. White to off-white granular fill.   </paragraph>
                        <paragraph> Bottlesof 100, NDC60505-4744-01   </paragraph>
                        <paragraph> Capsules 70 mg: Hard gelatin capsule with light blue opaque body and medium orange opaque cap. Imprinted APO L70 in black ink. White to off-white granular fill.   </paragraph>
                        <paragraph> Bottlesof 100, NDC60505-4745-01</paragraph>
                     </text>
                     <effectiveTime value="20220125"/>
                  </section>
               </component>
               <component>
                  <section ID="_8037b729-1567-ce6f-722b-35d94052a5c3">
                     <id root="9e0ab5ac-a936-8210-5ed7-8eaefb1050b8"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>16.2  StorageandHandling</title>
                     <text>
                        <paragraph>Dispense in a tight, light-resistant container as defined in the USP.</paragraph>
                        <paragraph>Store at room temperature, 20C to 25C (68F to 77F). Excursions permitted between 15C and 30C (59F to 86F) [see USP Controlled Room Temperature].</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20231103"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="INFORMATION_FOR_PATIENTS">
               <id root="69ad924f-8f49-b992-caf1-4d7510deeb7c"/>
               <code code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Abuse, Misuse, and Addiction</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>Educate patients and their families about the risks of abuse, misuse, and addiction oflisdexamfetamine dimesylate capsules, which can lead to overdose and death, and proper disposal of any unused drug <content styleCode="italics">[seeWarnings and Precautions (5.1), Drug Abuse and Dependence (9.2), Overdosage (<linkHtml href="#OVERDOSAGE">10</linkHtml>)]</content>. Advisepatients to store lisdexamfetamine dimesylate capsules in a safe place, preferably locked, and instruct patients to not givelisdexamfetamine dimesylate capsules to anyone else.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Risks to Patients with Serious Cardiac Disease</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>Advise patients that there are  potential risks to patients with serious cardiac disease, including sudden death,withlisdexamfetamine dimesylate capsulesuse.Instruct patientstocontact a healthcare provider immediately if they develop symptoms such as exertional chest pain,unexplained syncope, or other symptoms suggestive of cardiac disease <content styleCode="italics">[see Warnings andPrecautions(<linkHtml href="#_6dc62472-9038-1776-e43e-30fa4c123dd3">5.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Increased Blood Pressure and Heart Rate</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>Instruct patients that lisdexamfetamine dimesylate capsules can cause elevations of their blood pressure and pulse rate andtheyshould be monitored for such effects.</paragraph>
                  <paragraph>
                     <content styleCode="underline">PsychiatricAdverse Reactions</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>Advisepatients thatlisdexamfetamine dimesylate capsulesatrecommendeddosesmaycausepsychoticormanicsymptoms even in patients without prior history of psychotic symptoms or mania <content styleCode="italics">[see Warnings andPrecautions(<linkHtml href="#_05b1693a-479c-425e-2e57-26a72f39fe27">5.4</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Long-Term Suppression of Growth in Pediatric Patients</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>Advise patients that lisdexamfetamine dimesylate capsules may cause slowing of growth including weight loss <content styleCode="italics">[seeWarningsand Precautions (<linkHtml href="#_d2108e06-f1e5-9e1a-86a2-59273bf634b1">5.5</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Circulationproblems infingersandtoes[Peripheralvasculopathy,includingRaynauds phenomenon]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>Instruct patients beginning treatment with lisdexamfetamine dimesylate capsules about the risk of peripheral vasculopathy,including Raynauds phenomenon, and associated signs and symptoms:fingers or toes may feelnumb, cool, painful, and/or may change from pale, to blue, to red.Instruct patients to report totheir physician any new numbness, pain, skin color change, or sensitivity to temperature infingers or toes.Instruct patients to call their physician immediately with any signs ofunexplained wounds appearing on fingers or toes while taking lisdexamfetamine dimesylate capsules.Further clinicalevaluation (e.g., rheumatology referral) may be appropriate for certain patients <content styleCode="italics">[see WarningsandPrecautions (<linkHtml href="#_55b8f6eb-b923-8986-ec3f-cf5561192d43">5.6</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">SerotoninSyndrome</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>Caution patients about the risk of serotonin syndrome with concomitant use of lisdexamfetamine dimesylate capsules andother serotonergic drugs including SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl,lithium, tramadol, tryptophan, buspirone, St. Johns Wort, and with drugs that impair metabolismof serotonin (in particular MAOIs, both those intended to treat psychiatric disorders and alsoothers such as linezolid <content styleCode="italics">[see Contraindications (<linkHtml href="#CONTRAINDICATIONS">4</linkHtml>), Warnings and Precautions (<linkHtml href="#_b4410b38-5581-fcb5-39b3-9c4b0f013528">5.7</linkHtml>) and DrugInteractions (<linkHtml href="#_c2819f90-ae45-bce8-0cb9-c2f27b0dfc35">7.1</linkHtml>)]</content>.Advise patients to contact their healthcare provider or report to theemergencyroom if theyexperiencesigns or symptomsofserotonin syndrome.</paragraph>
                  <paragraph>
                     <content styleCode="underline">ConcomitantMedications</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>Advise patients to notify their physicians if they are taking, or plan to take, any prescription orover-the-counterdrugsbecausethereisapotentialforinteractions<content styleCode="italics">[seeDrugInteractions(<linkHtml href="#_c2819f90-ae45-bce8-0cb9-c2f27b0dfc35">7.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Motor and Verbal Tics, and Worsening of Tourettes Syndrome </content>
                  </paragraph>
                  <paragraph> Advise patients that motor and verbal tics and worsening of Tourettes Syndrome may occurduring treatment with lisdexamfetamine dimesylate capsules. Instruct patients to notify their healthcare provider ifemergence of new tics or worsening of tics or Tourettes syndrome occurs <content styleCode="italics">[see Warnings andPrecautions (<linkHtml href="#_7b73ed51-becd-2633-4ae4-e99d70d6df6b">5.8</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"> Pregnancy Registry </content>
                  </paragraph>
                  <paragraph> Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes inwomen exposed to lisdexamfetamine dimesylate capsules during pregnancy <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#PREGNANCY">8.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>Advise patients of the potential fetal effects from the use of lisdexamfetamine dimesylate capsules during pregnancy.Advise patients to notify their healthcare provider if they become pregnant or intend to becomepregnantduring treatmentwith lisdexamfetamine dimesylate capsules <content styleCode="italics">[seeUsein SpecificPopulations(<linkHtml href="#PREGNANCY">8.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>Advise women not to breastfeed if they are taking lisdexamfetamine dimesylate capsules <content styleCode="italics">[see Use in Specific Populations(<linkHtml href="#LABOR_AND_DELIVERY">8.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Administration Instructions</content>
                  </paragraph>
                  <list>
                     <item>Capsules:Advise patientstotakethecapsules wholeorempty andmixtheentirecontents withyogurt, water, or orange juice. Advise patients to consume the mixture immediately and not tostorefor future use <content styleCode="italics">[seeDosage andAdministration (<linkHtml href="#_84b0066f-fad5-120f-e954-9929b2b53b22">2.2</linkHtml>)]</content>.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline"/> Dispense with Medication Guide available at <content styleCode="underline">https://www.apotex.com/products/us/mg.asp</content>
                  </paragraph>
                  <paragraph>All registered trademarks are the property of their respective owners. <content styleCode="bold"></content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">APOTEX INC.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">LISDEXAMFETAMINE DIMESYLATE CAPSULES</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg</content>
                  </paragraph>
                  <table frame="void">
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Manufactured by:</content>
                              <br/> Frontida Biopharm, LLC <br/>1100 Orthodox Street <br/> Philadelphia, PA 19124 <br/> USA </td>
                           <td>
                              <content styleCode="bold">Manufactured for:</content>
                              <br/> Apotex Corp. <br/>Weston, Florida <br/> USA 33326  </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph> Rev. 5</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20231117"/>
            </section>
         </component>
         <component>
            <section ID="_839ed5f1-7321-2707-5322-23d009e40311">
               <id root="73ed05e3-dadc-d2eb-3048-cb7e427a8f38"/>
               <code code="42231-1" displayName="SPL MEDGUIDE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>MEDICATION GUIDE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Lisdexamfetamine</content>
                     <content styleCode="bold">D</content>
                     <content styleCode="bold">imesylate </content>(lis dexam fet a meen dye mes i late)<content styleCode="bold"> Capsules,CII</content>
                  </paragraph>
                  <paragraph> Medication Guide available at <content styleCode="underline">https://www.apotex.com/products/us/mg.asp</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Whatisthemostimportant informationIshouldknowaboutlisdexamfetamine dimesylate capsules?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Lisdexamfetamine dimesylate capsulesmaycauseserious sideeffects,including:</content>
                  </paragraph>
                  <list>
                     <item>
                        <content styleCode="bold">Abuse<content styleCode="bold">,misuse, and addiction.</content>
                        </content>Lisdexamfetamine dimesylate capsules has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of lisdexamfetamine dimesylate capsules, other amphetamine containing medicines, and methylphenidate containing medicines, can lead to overdose and death. The risk of overdose and death is increased with higher doses of lisdexamfetamine dimesylate capsules or when it is used in ways that are not approved, suchas snorting or injection.</item>
                     <item>Your healthcare provider should check you or your childs risk for abuse, misuse, and addiction before starting treatment with lisdexamfetamine dimesylate capsules and will monitor you or your child during treatment.</item>
                     <item>Lisdexamfetamine dimesylate capsules may lead to physical dependence after prolonged use, even if taken as directed by your healthcare provider.</item>
                     <item>Do not give lisdexamfetamine dimesylate capsules to anyone else. See <content styleCode="bold">What is </content>
                        <content styleCode="bold">lisdexamfetamine dimesylate capsules</content>
                        <content styleCode="bold">?</content> for more information.</item>
                     <item>Keep lisdexamfetamine dimesylate capsules in a safe place and properly dispose of any unused medicine. See "<content styleCode="bold">How should I store </content>
                        <content styleCode="bold">lisdexamfetamine dimesylate capsules</content>
                        <content styleCode="bold">?</content>" for more information.</item>
                     <item>Tell your healthcare provider if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs.<paragraph/>
                     </item>
                     <item>
                        <content styleCode="bold">Risks for people with serious heart disease. </content>Sudden death has happened in people who have heart defects or other serious heart disease.<paragraph>Your healthcare provider should check you or your child carefully for heart problems before starting treatment with lisdexamfetamine dimesylate capsules. Tell your healthcare provider if you or your child have any heart problems, heart disease, or heart defects.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Call your healthcare provider right away or go to the nearest hospital emergency room right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with lisdexamfetamine dimesylate capsules</content>
                           <content styleCode="bold">.</content>
                        </paragraph>
                     </item>
                     <item>
                        <paragraph>
                           <content styleCode="bold"/>
                           <content styleCode="bold">Increased blood pressure and heart rate.</content>
                        </paragraph>
                     </item>
                  </list>
                  <paragraph>Your healthcare provider should check you or your childs blood pressure and heart rate regularly during treatment with lisdexamfetamine dimesylate capsules.</paragraph>
                  <list>
                     <item>
                        <content styleCode="bold">Mental(psychiatric)problems,including:</content>
                        <list>
                           <item>neworworsebehaviorandthought problems</item>
                           <item>neworworsebipolarillness</item>
                           <item>new psychotic symptoms (such as hearing voices, or seeing or believing things that are not real) or new manicsymptoms<paragraph/>
                           </item>
                        </list>
                        <paragraph>Tell your healthcare provider about any mental problems you or your child have or about a family history of suicide,bipolarillness, ordepression.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Call your healthcare provider right away if you or your child have any new or worsening mental symptomsor problems during treatment with lisdexamfetamine dimesylate capsules, especially hearing voices, seeing or believing things that arenotreal,ornewmanic symptoms.</content>
                        </paragraph>
                        <paragraph/>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Whatarelisdexamfetamine dimesylate capsules?</content>
                  </paragraph>
                  <paragraph>Lisdexamfetamine dimesylate capsules areacentralnervoussystem (CNS)stimulantprescriptionmedicineusedforthetreatmentof:</paragraph>
                  <list>
                     <item>Attention Deficit Hyperactivity Disorder (ADHD) in adults and children 6 years of age and older. Lisdexamfetamine dimesylate capsules may helpincreaseattentionanddecreaseimpulsivenessandhyperactivityinpeoplewithADHD.</item>
                     <item>Moderate to severe binge eating disorder (BED) in adults. Lisdexamfetamine dimesylate capsules may help reduce the number of binge eating daysinpeople withBED.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Lisdexamfetamine dimesylate capsulesarenotforuseinchildren under6yearsofagewithADHD</content>.</paragraph>
                  <paragraph>Lisdexamfetamine dimesylate capsules are not for weight loss. It is not known if lisdexamfetamine dimesylate capsules are safe and effective for the treatment of obesity. Itisnotknowniflisdexamfetamine dimesylate capsulesaresafeandeffectiveforuseinchildrenwithBED.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lisdexamfetamine dimesylate capsules are a federally controlled substance (CII) because it contains lisdexamfetamine dimesylate that can be a target for people who abuse prescription medicines or street drugs. </content>Keep lisdexamfetamine dimesylate capsules in a safe place toprotect it from theft. Never give your lisdexamfetamine dimesylate capsules to anyone else because it may cause death or harm them. Selling or givingawaylisdexamfetamine dimesylate capsulesmayharmothers andisagainstthelaw.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Donottakelisdexamfetamine dimesylate capsulesifyouoryourchildare:</content>
                  </paragraph>
                  <list>
                     <item>allergic to amphetamine products or any of the ingredients in lisdexamfetamine dimesylate capsules. See the end of this Medication Guide for acompletelistofingredientsinlisdexamfetamine dimesylate capsules.</item>
                     <item>taking,orhavestoppedtaking inthelast14days, amedicinecalled aMonoamineOxidase Inhibitor(MAOI).</item>
                     <item>beingtreated withtheantibioticlinezolidorintravenousmethyleneblue.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Before taking lisdexamfetamine dimesylate capsules, tell your healthcare provider about all medical conditions, including if you or yourchild:</content>
                  </paragraph>
                  <list>
                     <item>haveheartproblems, heartdisease, heart defects,orhighbloodpressure</item>
                     <item>have mental problems including psychosis, mania, bipolar illness, or depression or have a family history of suicide,bipolar illness,ordepression</item>
                     <item>havecirculationproblems infingersandtoes</item>
                     <item>have kidney problems</item>
                     <item>have or had repeated movements or sounds (tics) or Tourettes syndrome, or have a family history of tics or Tourettes syndrome</item>
                     <item>arepregnantorplantobecomepregnant.Lisdexamfetamine dimesylate capsulesmayharmtheunbornbaby.<list>
                           <item>There is a pregnancy registry for females who are exposed to lisdexamfetamine dimesylate capsules during pregnancy. The purpose of the registry is to collect information about the health of females exposed to lisdexamfetamine dimesylate capsules and their baby. If you or your child becomes pregnant during treatment with lisdexamfetamine dimesylate capsules, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychostimulants at 1-866-961-2388 or visit online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/adhd-medications/. </item>
                        </list>
                     </item>
                     <item>are breastfeeding or plan to breastfeed. Lisdexamfetamine dimesylate passes into breast milk. You should not breastfeed duringtreatment with lisdexamfetamine dimesylate capsules. Talk to your healthcare provider about the best way to feed the baby during treatment withlisdexamfetamine dimesylate capsules.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider about all the medicines that you or your child take, </content>including prescription and over-the-countermedicines, vitamins, and herbalsupplements.</paragraph>
                  <paragraph>Lisdexamfetamine dimesylate capsules can affect the way other medicines work and other medicines may affect how lisdexamfetamine dimesylate capsules works. Takinglisdexamfetamine dimesylate capsules with other medicines can cause serious side effects. Sometimes the doses of other medicines will need tobechangedwhiletakinglisdexamfetamine dimesylate capsules.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Especiallytellyourhealthcareproviderifyouoryourchildtake:</content>
                  </paragraph>
                  <table>
                     <tbody>
                        <tr>
                           <td>
                              <list>
                                 <item>selectiveserotoninreuptakeinhibitors(SSRIs)</item>
                                 <item>medicinesusedtotreatmigraineheadaches called triptans</item>
                                 <item>lithium</item>
                                 <item>tramadol</item>
                                 <item>buspirone</item>
                              </list>
                           </td>
                           <td>
                              <list>
                                 <item>serotoninnorepinephrinereuptakeinhibitors(SNRIs)</item>
                                 <item>tricyclicantidepressants</item>
                                 <item>fentanyl</item>
                                 <item>tryptophan</item>
                                 <item>St. JohnsWort</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Keep a list of all medicines to show your healthcare provider and pharmacist when you get a new medicine. Yourhealthcareproviderwilldecide iflisdexamfetamine dimesylate capsulescanbetakenwithother medicines.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not start any new medicine during treatment with lisdexamfetamine dimesylate capsules without talking to your healthcare provider first.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Howshouldlisdexamfetamine dimesylate capsulesbetaken?</content>
                  </paragraph>
                  <list>
                     <item>Takelisdexamfetamine dimesylate capsulesexactlyasprescribedbyyourhealthcareprovider.</item>
                     <item>Yourhealthcareprovider maychangethedoseifneeded.</item>
                     <item>Takelisdexamfetamine dimesylate capsule1timeeachdayinthemorningwithorwithout food.</item>
                     <item>Lisdexamfetamine dimesylate capsulescomesincapsules.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Takinglisdexamfetamine DimesylateCapsules:</content>
                  </paragraph>
                  <list>
                     <item>Lisdexamfetamine dimesylatecapsules maybeswallowedwhole.</item>
                     <item>If lisdexamfetamine dimesylate capsules cannot be swallowed whole, the capsule may be opened and the entire contents sprinkledontoyogurt, orpouredintowaterororangejuice.<list>
                           <item>Using a spoon, break apart any powder that is stuck together. Stir the lisdexamfetamine dimesylate capsule powder and yogurt,water, or orange juiceuntiltheyarecompletely mixedtogether.</item>
                           <item>Swallow all the yogurt, water, or orange juice mixture right away. <content styleCode="bold">Do not </content>store the yogurt, water, or orange juicemixture.</item>
                           <item>Itisnormaltoseeafilmycoating ontheinsideofyourglassorcontainerafteryoueatordrinkallthelisdexamfetamine dimesylate capsulemixture.</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>If you or your child take too much lisdexamfetamine dimesylate capsules, call your healthcare provider or Poison Help line at 1-800-222-1222orgoto the nearest hospitalemergency roomrightaway.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of lisdexamfetamine dimesylate capsules?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Lisdexamfetamine dimesylate capsulesmaycauseserious sideeffects,including:</content>
                  </paragraph>
                  <list>
                     <item>See<content styleCode="bold">WhatisthemostimportantinformationIshould knowaboutlisdexamfetamine dimesylate capsules?</content>
                     </item>
                     <item>
                        <content styleCode="bold">Slowingofgrowth(height andweight)inchildren.</content>Childrenshouldhavetheirheightandweightcheckedoftenduring treatment with lisdexamfetamine dimesylate capsules. Lisdexamfetamine dimesylate capsules treatment may be stopped if your child is not growing or gainingweight.</item>
                     <item>
                        <content styleCode="bold">Circulationproblems infingersandtoes(Peripheralvasculopathy,includingRaynauds phenomenon).</content> Signsandsymptomsmayinclude:<list>
                           <item>Fingersortoesmayfeelnumb,cool,painful</item>
                           <item>Fingersortoesmaychangecolor frompale,toblue,tored</item>
                        </list>
                        <paragraph>Tell your healthcare provider if you or your child have numbness, pain, skin color change, or sensitivity totemperaturein your fingers or toes.</paragraph>
                        <paragraph/>
                        <paragraph>Call your healthcare provider right away if you or your child have any signs of unexplained wounds appearing onfingers or toes duringtreatmentwithlisdexamfetamine dimesylate capsules.</paragraph>
                     </item>
                     <item>
                        <paragraph>
                           <content styleCode="bold"/>
                           <content styleCode="bold">New or worsening tics or worsening Tourettes syndrome. </content>Tell your healthcare provider if you or your child get any new or worsening tics or worsening Tourettes syndrome during treatment with lisdexamfetamine dimesylate capsules.</paragraph>
                     </item>
                     <item>
                        <paragraph>
                           <content styleCode="bold">Serotonin Syndrome. </content>A potentially life-threatening problem called serotonin syndrome may happen whenLisdexamfetamine dimesylate capsules are taken with certain other medicines. Stop taking lisdexamfetamine dimesylate capsules and call your healthcare provider or go to the nearest hospital emergency room right away if you or your child develop any of the following signs andsymptoms ofserotoninsyndrome:</paragraph>
                        <table>
                           <tbody>
                              <tr>
                                 <td>
                                    <list>
                                       <item>agitation</item>
                                       <item>flushing</item>
                                       <item>coma</item>
                                       <item>lossofcoordination</item>
                                       <item>dizziness</item>
                                       <item>seeingorhearingthingsthatarenotreal(hallucination)</item>
                                       <item>highbodytemperature(hyperthermia)</item>
                                    </list>
                                 </td>
                                 <td>
                                    <list>
                                       <item>fast heartbeat</item>
                                       <item>seizures</item>
                                       <item>sweating</item>
                                       <item>confusion</item>
                                       <item>tremors,stiff muscles,ormuscle twitching</item>
                                       <item>changes inblood pressure</item>
                                       <item>nausea,vomiting, diarrhea</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Themostcommonsideeffectsoflisdexamfetamine dimesylate capsulesinchildren 6to17yearsoldandadults withADHDinclude:</content>
                  </paragraph>
                  <table>
                     <tbody>
                        <tr>
                           <td>
                              <list>
                                 <item>lossof appetite(anorexia)</item>
                                 <item>decreasedappetite</item>
                                 <item>diarrhea</item>
                                 <item>drymouth</item>
                                 <item>troublesleeping</item>
                                 <item>stomachpain</item>
                              </list>
                           </td>
                           <td>
                              <list>
                                 <item>anxiety</item>
                                 <item>weightloss</item>
                                 <item>dizziness</item>
                                 <item>irritability</item>
                                 <item>nausea</item>
                                 <item>vomiting</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Themostcommonsideeffectsoflisdexamfetamine dimesylate capsulesinadults withBEDinclude:</content>
                  </paragraph>
                  <table>
                     <tbody>
                        <tr>
                           <td>
                              <list>
                                 <item>drymouth</item>
                                 <item>decreasedappetite</item>
                                 <item>constipation</item>
                                 <item>anxiety</item>
                              </list>
                           </td>
                           <td>
                              <list>
                                 <item>troublesleeping</item>
                                 <item>increasedheartrate</item>
                                 <item>feelingjittery</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Thesearenotallthepossiblesideeffectsoflisdexamfetamine dimesylate capsules. </paragraph>
                  <paragraph>Callyourdoctor formedicaladvice aboutsideeffects. Youmayreport sideeffectstoFDAat1-800-FDA-1088.</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">HowshouldIstorelisdexamfetamine dimesylate capsules?</content>
                  </paragraph>
                  <list>
                     <item>Store lisdexamfetamine dimesylate capsules in a safe place (like a locked cabinet) and in a tightly closed container at room temperature between68F to 77F (20C to 25C).</item>
                     <item>Protect lisdexamfetamine dimesylate capsules from light.</item>
                     <item>Dispose of remaining, unused, or expired lisdexamfetamine dimesylate capsules by a medicine take-back program at a U.S. Drug Enforcement Administration (DEA) authorized collection site. If no take-back program or DEA authorized collector is available, mix lisdexamfetamine dimesylate capsule with an undesirable, nontoxic substance such as dirt, cat litter, or used coffee grounds to make it less appealing to children and pets. Place the mixture in a containersuchasasealedplastic bagand throwawaylisdexamfetamine dimesylate capsuleinthehouseholdtrash. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keeplisdexamfetamine dimesylate capsulesandallmedicinesoutofthereachofchildren.</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Generalinformationaboutthesafeandeffective useoflisdexamfetamine dimesylate capsules.</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.Do not uselisdexamfetamine dimesylate capsules for a condition for which it was not prescribed. Do not give lisdexamfetamine dimesylate capsules to other people, even if they have thesame symptoms that you have. It may harm them and it is against the law. You can ask your pharmacist or healthcare providerforinformationaboutlisdexamfetamine dimesylate capsulesthatiswrittenforhealthcareprofessionals.</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Whataretheingredientsinlisdexamfetamine dimesylate capsules?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Activeingredient:</content>lisdexamfetaminedimesylate</paragraph>
                  <paragraph>
                     <content styleCode="bold">Capsule Inactive Ingredients: </content>colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and microcrystalline cellulose.The capsule shells contain gelatin, titanium dioxide, and one or more of the following: D&amp;C Red #28 (70 mg), FD&amp;C Blue#1 (40 mg, 50 mg, 60 mg and 70 mg), FD&amp;CRed#3 (10 mg and 30 mg), FD&amp;C Red #40 (70 mg), FD&amp;CYellow#6 (30 mg and 70 mg), iron oxide black (40 mg), and iron oxide yellow (20 mg and 40 mg). The imprinting ink of the 10 mg capsules contains iron oxide black, potassium hydroxide, propylene glycol, shellac, and strong ammonia solution. The imprinting ink of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac glaze.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">APOTEX INC.</content>
                        <content styleCode="bold"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">LISDEXAMFETAMINE DIMESYLATE CAPSULES</content>
                     </content>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg</content>
                  </paragraph>
                  <table>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Manufactured by:</content>
                              <br/> Frontida Biopharm, LLC <br/>1100 Orthodox Street <br/>Philadelphia, PA 19124 <br/> USA </td>
                           <td>
                              <content styleCode="bold">Manufactured for:</content>
                              <br/> Apotex Corp. <br/>Weston, Florida <br/> USA 33326  <paragraph/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Rev. 5</paragraph>
                  <paragraph>ThisMedicationGuidehasbeenapprovedbytheU.S.FoodandDrugAdministration. </paragraph>
                  <paragraph> Revised:11/2023</paragraph>
               </text>
               <effectiveTime value="20231231"/>
            </section>
         </component>
         <component>
            <section ID="_8a9e88fb-04c9-9b48-5bfc-0b39f3048104">
               <id root="ac2ace5b-312b-cf58-746c-a735e58ac7dd"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 10 mg Capsule Bottle Label</content>
                  </paragraph>
                  <paragraph>NDC 60505-4739-1</paragraph>
                  <paragraph>Lisdexamfetamine Dimesylate Capsules </paragraph>
                  <paragraph>10 mg </paragraph>
                  <paragraph>CII </paragraph>
                  <paragraph>Rx only </paragraph>
                  <paragraph>100 CAPSULES </paragraph>
                  <paragraph>Apotex Corp</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM102103952158"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240926"/>
            </section>
         </component>
         <component>
            <section ID="_aa6f6cc4-2b42-44ae-392c-7355d7603754">
               <id root="a53eb25a-9677-11bd-8431-55af7fb6dc87"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 20 mg Capsule Bottle Label</content>
                  </paragraph>
                  <paragraph>NDC 60505-4740-1</paragraph>
                  <paragraph>Lisdexamfetamine Dimesylate Capsules </paragraph>
                  <paragraph>20 mg </paragraph>
                  <paragraph>CII </paragraph>
                  <paragraph>Rx only </paragraph>
                  <paragraph>100 CAPSULES </paragraph>
                  <paragraph>Apotex Corp</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM544434860732"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20240926"/>
            </section>
         </component>
         <component>
            <section ID="_e1aff6fa-1ef9-a62f-ad0d-75adc517e974">
               <id root="d098e109-97c3-42cc-2b1e-d3a8cfbc585f"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 30 mg Capsule Bottle Label</content>
                  </paragraph>
                  <paragraph>NDC 60505-4741-1</paragraph>
                  <paragraph>Lisdexamfetamine Dimesylate Capsules </paragraph>
                  <paragraph>30 mg </paragraph>
                  <paragraph>CII </paragraph>
                  <paragraph>Rx only </paragraph>
                  <paragraph>100 CAPSULES </paragraph>
                  <paragraph>Apotex Corp </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM635294604935"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240926"/>
            </section>
         </component>
         <component>
            <section ID="_997f0838-0ecb-0ad2-643a-a6ce80a9759b">
               <id root="45973c13-2522-b5b4-a45a-aa9fe9b2765e"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 40 mg Capsule Bottle Label </content>
                  </paragraph>
                  <paragraph>NDC 60505-4742-1 </paragraph>
                  <paragraph>Lisdexamfetamine Dimesylate Capsules </paragraph>
                  <paragraph>40 mg </paragraph>
                  <paragraph>CII </paragraph>
                  <paragraph>Rx only </paragraph>
                  <paragraph>100 CAPSULES </paragraph>
                  <paragraph>Apotex Corp</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM335033868044"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20240926"/>
            </section>
         </component>
         <component>
            <section ID="_fef7f1b5-dc18-1365-265b-1db3d799cf35">
               <id root="1f697d85-ce0f-86f1-70e1-00d8e28ee4bb"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 50 mg Capsule Bottle Label </content>
                  </paragraph>
                  <paragraph>NDC 60505-4743-1 </paragraph>
                  <paragraph>Lisdexamfetamine Dimesylate Capsules </paragraph>
                  <paragraph>50 mg </paragraph>
                  <paragraph>CII </paragraph>
                  <paragraph>Rx only </paragraph>
                  <paragraph>100 CAPSULES</paragraph>
                  <paragraph> Apotex Corp</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM301125462943"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240926"/>
            </section>
         </component>
         <component>
            <section ID="_154dc4e3-6cb9-08ea-9653-07698cec6bbf">
               <id root="b77acdac-7966-548c-a4c2-7e6528fa5214"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 60 mg Capsule Bottle Label </content>
                  </paragraph>
                  <paragraph>NDC 60505-4744-1 </paragraph>
                  <paragraph>Lisdexamfetamine Dimesylate Capsules </paragraph>
                  <paragraph>60 mg </paragraph>
                  <paragraph>CII </paragraph>
                  <paragraph>Rx only </paragraph>
                  <paragraph>100 CAPSULES</paragraph>
                  <paragraph> Apotex Corp</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM388766615699"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240926"/>
            </section>
         </component>
         <component>
            <section ID="_fb2ac477-1795-f470-2757-abae2c51b912">
               <id root="632b0b21-2757-c13a-83a5-eda4905af941"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 70 mg Capsule Bottle Label </content>
                  </paragraph>
                  <paragraph>NDC 60505-4745-1 </paragraph>
                  <paragraph>Lisdexamfetamine Dimesylate Capsules </paragraph>
                  <paragraph>70 mg </paragraph>
                  <paragraph>CII </paragraph>
                  <paragraph>Rx only </paragraph>
                  <paragraph>100 CAPSULES</paragraph>
                  <paragraph> Apotex Corp</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM73930055298"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240926"/>
            </section>
         </component>
      </structuredBody>
   </component>
</document>